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Since the discovery of Mendel’s laws, one of the most challenging problems in genetic
research has been to locate and characterize genetic variants that cause human disease.
Although thousands of disease-associated genetic variants have been discovered, many
remain unknown. New methods are needed to facilitate the discovery process. Here, we
present new methodology to improve detection of these genetic variants for genotyping
imputation, Copy Number Variations (CNV) and sequencing data.

Currently, imputation is widely used to evaluate the evidence for association at genetic
markers that are not directly-genotyped. However, imputation can be problematic
especially when a genetic variant has low minor allele frequency. We present a new
statistic, the imputation quality score, developed to better differentiate well-imputed and
poorly-imputed SNPs. It is particularly useful for SNPs with low minor allele frequency
and datasets that are genotyped on different platforms.
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CNV calling, on the other hand, is not reliable. We developed a statistical method for
estimating sensitivity and positive predictive rate, and evaluated the relative performance
of CNV calling on a genome wide scale. We found that the positive predictive rate
increases with the number of probes and the size of CNVs. We also noticed that CNVs
reported by multiple programs have a higher reproducibility rate and positive predictive
rate. This method was applied to the dataset from the Study of Addiction: Genetics and
Environment. Our analysis revealed that CNVs in 6q14.1 (P= 1.04 x10-6) and 5q13.2 (P=
3.37 x10 -4) are significantly associated with alcohol dependence after adjusting for
multiple tests. Evidence also suggested that CNVs at 5q13.2 increase the risk for alcohol
dependence by lowering conscientiousness, or more specifically, self-discipline.

As genetics is looking towards the future with sequencing data, improved methods are
needed for rare variants. By taking advantage of the simulation data from the Genetic
Analysis Workshop, we integrated both the collapsing method and the family data
method in an attempt to increase power for rare variants. We concluded that this
combinational approach offers a substantial power boost for certain causal genes, and is
therefore worth further investigation.

By focusing on improving the interpretation of data from imputation, CNV calling and
sequencing, our work parallels the development of genetic research over the past few
years, provides a direction for on-going methods development, and will be useful for
future research endeavors.
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Chapter 1: Introduction
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A BRIEF REVIEW OF METHODS IN STATISTICAL GENETICS RESEARCH
The hereditary nature of different phenotypes lies secretly in the genome. The goal of
genetic research is to identify these secret genetic components that affect these different
phenotypes. Since Mendel first discovered the law of inheritance, the rapid development
of technology has revolutionized technologies we can use to study genetics, and
consequently the statistical methods to process the information generated by these new
technologies.

One of the most important research areas in human genetics in the last century has been
the effort to link various traits and diseases to a relatively-large region in the human
genome. This would not have been possible without the discovery of Restriction
Fragment Length Polymorphisms (RFLPs), Variable Number Tandem Repeat (VNTR)
and Microsatellite (or simple sequence repeats) [1, 2]. Due to limited number of these
genetic markers and also partly due to technical challenges, these genetic markers can
only cover an extremely small fraction of total variants in the entire genome. Fortunately,
it was known at that time that the recombination frequency between the genetic marker
and a particular trait is correlated with the physical distance between the known genetic
marker and the underlying gene for the particular trait. Linkage thus maps the position of
underlying genes relative to known genetic markers in terms of recombination frequency.
The LOD score (logarithm of odds), developed by Newton E. Morton, is a statistical test
often used for linkage analysis in human. The LOD score compares the likelihood of
obtaining the test data if the two loci are indeed linked, to the likelihood of observing the
same data by chance. By convention, a LOD score greater than 3.0 is considered strong
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evidence for linkage, whereas smaller LOD scores indicate that linkage is less likely.
Linkage has proven to be successful, numerous trait and disease genes loci have been
found, and several new methods based on linkage have been developed [3].

More recently, the development of DNA microarray has made genome wide association
studies possible [4]. Rather than <10,000 genetic markers used in linkage studies, these
studies typically genotype 100,000–1,000,000 variants in each of the individuals being
studied. As of today, some commercial DNA microarrays can genotype more than
2,500,000 Single Nucleotide Polymorphisms (SNPs). The total number of SNPs that can
be genotyped in a DNA microarray is still far less than the total number of genetic
variants in the human genome, but SNPs can tag surrounding blocks of ancient DNA
(haplotypes). This property is often described in the term of linkage disequilibrium (LD).
This huge number of SNPs provides a relatively sufficient coverage for the entire human
genome, which underlies the rational of genome wide association studies. In 2005, the
first widely replicable genome wide association study reported association between the
complement factor H (CFH) gene and age-related macular degeneration (AMD) [5]. This
discovery was the earliest of its kind in part because variation at CFH has a large effect—
greater than fourfold—on AMD risk. In 2007, the Wellcome Trust Case Control
Consortium carried out genome-wide association studies for the diseases of coronary
heart disease, type 1 diabetes, type 2 diabetes, rheumatoid arthritis, Crohn's disease,
bipolar disorder, and hypertension[4]. This study was one of the largest studies at that
time, including more than 14,000 cases of seven common diseases and 3,000 shared
controls. To date, more than 1200 genome wide association studies have been conducted,
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over 200 diseases and traits have been examined, and about 4000 SNP associations have
been found [6].

However, it has been estimated that more than 10 million common SNPs are likely to
exist in the human genome [7]. Therefore, a typical genome wide association study can
only examine a very small fraction of these common SNPs, and millions of known
common variants have to be ignored. As described previously, SNPs can tag surrounding
genetic variants; therefore, it is also possible to infer genotypes at unobserved SNPs
based on multiple surrounding genetic variants in a procedure commonly known as
imputation, leading to improved power. Imputation typically needs a reference panel that
includes a large number of genetic variants. Study samples genotyped are compared to
this reference panel and shared haplotype are then guessed and assigned with different
probabilities. Missing genotypes for each study sample can be predicted by matching
reference haplotypes [8]. A recent type 2 diabetes study showed that the accuracy of
imputation is high. In this study, the investigators compared imputed genotypes generated
in silico with experimental genotypes generated in the lab. Their results showed excellent
concordance between genotype calls, with an overall concordance rate of >98% between
genotyped and imputed SNPs [9]. Since there is almost no cost associated with
imputation, and the benefit to have more in silico genotyped SNPs is obvious, imputation
has become very popular and paves the way for meta-analysis that combines dozens of
different studies.
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Most variants found in genome wide association studies so far confer relatively small
increments in risk (1~1.5 fold), and explain only a small proportion of heritability—the
portion of phenotypic variance in a population attributable to additive genetic factors [10].
For example, the estimated heritability for human height is over 80%, so far at least 40
loci have been found, yet they together explain only about 5% of phenotypic variance
[11]. Many investigators question how the remaining, ‘missing’ heritability can be
explained. Several potential answers are offered. Some investigators suggest that copy
number variation (CNV) may contribute a substantial amount to the heritability, while
some others propose that the missing heritability may lie in rare variants, which cannot be
well captured by current genome wide association studies.

Copy Number Variations usually refer to duplications or deletions of a particular segment
in the human genome. Evidence has shown that CNVs can change the expression level of
genes in or near these CNV regions[12]. In the past, CNVs are usually discovered by
hypothesis-driven lab experiments at a limited number of target regions. The advent of
genome-wide association studies (GWAS) has led to the possibility of discovering CNVs
across the genome. Many CNV detection programs have been developed for this purpose,
including CNVpartition, PennCNV, and QuantiSNP. Many studies have identified CNVs
that may be associated with diseases [13-19]. Now it is not uncommon practice that many
research groups will search CNVs after completing genome wide association studies.

Different from the common disease common variant hypothesis, the rare variant
hypothesis proposes that a significant proportion of total variation may be due to the
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effects of a large number of low frequency genetic variants [20]. Some rare variants may
be individually rare, but cumulatively large in number in the population, while others
may be extremely private, and only exist in certain families. These rare variants cannot be
tagged or imputed by surrounding common SNPs that are genotyped in genome wide
association studies. The only way to find these rare variants is to do high-throughput
sequencing, which is not economically feasible until just one or two years ago.

6

IMPUTATION ACCURACY
In statistics, agreement statistic describes the degree of agreement among raters. A large
number of statistics are designed to assess agreement. Different statistics are often
appropriate under certain conditions. One of the most commonly used statistics is
concordance rate, which is the percentage of agreed paired measures among all paired
measures (Table 1.1).

Concordance rate is simple and straight forward, and gives a quick answer to evaluate
agreement. Some other statistics are more applicable in a more complicated situation, for
example joint-probability of agreement, Cohen's kappa and the related Fleiss' kappa,
inter-rater correlation, concordance correlation coefficient and intra-class correlation [21].
Many methods for genetic research, including linkage analysis, genome wide association
studies and imputation, depend heavily on the agreement statistic, because it addresses an
important issue − the data quality. For example, in linkage analysis, genotyping errors
are spotted by comparing genotypes of children and parents [22]. In genome wide
association studies, duplicate samples are often included in a study design to assess SNP
genotyping accuracy [23]. For imputation, the imputed genotypes are often compared to
experimental genotypes generated in the lab [9].

More specifically, the commonly used concordance rate in imputation is defined by the
proportion of correctly classified genotypes, or equivalently by the discrepancy rate
7

between imputed and observed genotypes [24]. Evidence has shown that imputation has a
high concordance rate and provides a cost efficient way to improve power [9]. But as the
current research trend shifts toward genetic variants with low allele frequency, the
commonly used concordance rate is not sufficient to evaluate imputation reliability, and
can be misleading and even wrong in some scenarios. Table 1.1 shows that the
occurrence of a positive reading (“+”) is 1 in 10. The positive readings in Test 1 and Test
2 do not match with each other. However, according to the formula, the concordance rate
is 0.8. This concordance rate is largely due to chance agreement of negatives.
This phenomenon becomes more serious when the frequency of positive readings
continues to decrease. Because of chance agreement, an uncommon SNP has a higher
apparent concordance rate than a common SNP. By randomly assigning the two alleles of
a rare SNP, using only the MAF (<5%), an apparent accuracy greater than 90% can be
reached if it is measured by the concordance rate [25, 26]. A related issue in statistical
genetics is the difficulty of combining datasets that are genotyped on different platforms.
Different platforms have different sets of SNPs and imputation is necessary to predict
SNPs that are not genotyped in one platform or the other. If the concordance rate is used
for quality control, the following analysis will report an enormous number of false
positives [26].
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THE RELIABILITY OF CNV DETECTION USING SNP GENOTYPING ARRAY
Copy Number Variations are a prevalent form of genetic variation. They are known as
duplications or deletions of a particular segment of DNA. The comprehensive
identification and validation of CNVs would greatly benefit the genetic research of
human disease. Previous experimental studies for CNV detection were mainly performed
by microarray comparative genomic hybridization (array- CGH) [27]. However, arrayCGH has limited sensitivity and poor resolution and is highly subject to the variation of
existing CNVs among unrelated samples that are used as a reference. The advancement
of SNP microarray makes it more suitable for genome wide CNV detection. A typical
DNA microarray provides total fluorescent intensity signals at each probe and the relative
ratio of the fluorescent signals between two alleles at each SNP probe. These signals are
often referred as the “log R Ratio” and “B Allele Frequency” respectively [28]. CNVs
thus can be readily discovered by examining the pattern change of log R Ratio and B
Allele Frequency.

Many methods are available to identify CNVs from SNP microarray. Conventional
methods discover CNVs by averaging log R Ratio of probes in a sliding window, while
more sophisticated methods involve the hidden Markov model to assign different CNV
modes across the genome. Similar to rare SNPs, the majority of CNVs are not common in
the population. Therefore, CNVs called by these methods typically have an apparent high
concordance rate whereas other more appropriate measures indicate less confidence in
CNV calling. In our study, we have compared CNVs from duplicate samples. Despite a
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concordance rate as high as > 98%, only about half of CNVs can be reproduced in the
duplicate samples [29].

Due to poor reliability, CNV calls require further experimental validation. Quantitative
PCR is the most commonly used technique to validate CNVs. However, it is not
economically feasible − at least at this time − to validate all CNV calls across the genome
by experiments. Without experimental validation, these CNV calls have no experiment
validated results to be compared with and thus it is difficult to evaluate calling reliability.
Analysis based on these results may cause many false positives. This thesis aims to find
part of the solutions for this challenge.
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THE CHALLENGE OF DISCOVERING RARE VARIANTS
Genome-wide association studies have identified many common genetic variants that
contribute to complex diseases, but together they can only explain a small fraction of
total variation. Many researchers believe that a large number of genetic variants
contributing to disease susceptibility are yet to be discovered [30], and these genetic
variants are very likely to be genetic variants with low frequency [20].

Association analyses involving rare variants are not as easy as analyses involving
common variants. Power analysis has shown that in a standard case control study design,
the sample size needed to detect an association with a single rare variant dwarfs the
sample size of any current genome wide association studies (Figure 1.1).

Several methods have been proposed to overcome the power issue. One strategy involves
collapsing sets of rare variants into a single group, and then compares their collective
frequency between cases and controls [31]. Another strategy takes the family-based
approach, because in theory, individuals sharing the same rare variant can be more easily
recruited in the family-based study design. Currently, many investigators have ongoing
research in this area and there is no consensus among the research community on what is
the best approach.
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CONCLUSION
The field of statistical genetics has evolved rapidly in the past few years. New
technologies are introduced, and accordingly new methods are developed. The traditional
methods have proved to be extremely successful in genetic research, but they are not
sufficient to address challenging issues involved with the latest discoveries.

This work will mainly focus on imputation and CNV studies, partly due to the fact that
imputation and CNV studies have a higher error rate and therefore require more
sophisticated methods. It is also partly because most part of this research was done at the
time frame when imputation and CNV studies were in a rapid development period. The
development of new methods for imputation and CNV studies will be discussed in
Chapter 2 and Chapter 3 respectively. In Chapter 4, this work will cover the application
of these new methods in real datasets to facilitate the searching process for genetic
variants that are associated with alcohol dependence and further link alcohol dependence
with the “Big Five” factors in personality. Both of alcohol dependence and personality
have been proved to have a strong genetic component. One goal of this work is also to
cast light on the solutions for future genetic research. As whole genome sequencing will
become economically feasible in the years ahead, this work also covers a new method for
rare variants in the coming age of “common disease, rare variant.”
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Table 1.1 - Concordance rate
1

2

3

4

5

6

7

8

9

10

Test 1

+

-

-

-

-

-

-

-

-

-

Test 2

-

+

-

-

-

-

-

-

-

-

Concordance rate is defined as the percentage of agreed paired measures among all
paired measures. The concordance rate between Test 1 and Test 2 is 0.8.
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Figure 1.1 - The sample size required to detect rare variants

Adapted by permission from Macmillan Publishers Ltd: Nature reviews [30], copyright
2010
The x-axis indicates the ratio of the frequency of the allele in the case versus control
groups. The y-axis shows the sample size required to detect rare variants when type I
error rate is set to 10−9. These lines with different colors indicate the allele frequency in
control group.
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Chapter 2: A New Statistic to Evaluate Imputation Reliability

*This chapter is adapted from: Lin P et al. (2010) A New Statistic to Evaluate Imputation
Reliability. PLoS ONE 5(3): e9697. doi:10.1371/journal.pone.0009697.
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ABSTRACT
As the amount of data from genome wide association studies grows dramatically, many
interesting scientific questions require imputation to combine or expand datasets.
However, there are two situations for which imputation has been problematic: (1)
polymorphisms with low minor allele frequency (MAF), and (2) datasets where subjects
are genotyped on different platforms. Traditional measures of imputation cannot
effectively address these problems.

We introduce a new statistic, the imputation quality score (IQS). In order to differentiate
between well-imputed and poorly-imputed single nucleotide polymorphisms (SNPs), IQS
adjusts the concordance between imputed and genotyped SNPs for chance. We first
evaluated IQS in relation to minor allele frequency. Using a sample of subjects genotyped
on the Illumina 1M array, we extracted those SNPs that were also on the Illumina 550K
array and imputed them to the full set of the 1M SNPs. As expected, the average IQS
value drops dramatically with a decrease in minor allele frequency, indicating that IQS
appropriately adjusts for minor allele frequency. We then evaluated whether IQS can
filter poorly-imputed SNPs in situations where cases and controls are genotyped on
different platforms. Randomly dividing the data into "cases" and "controls", we extracted
the Illumina 550K SNPs from the cases and imputed the remaining Illumina 1M SNPs.
The initial Q-Q plot for the test of association between cases and controls was grossly
distorted (λ=1.15) and had 4016 false positives, reflecting imputation error. After filtering
out SNPs with IQS < 0.9, the Q-Q plot was acceptable and there were no longer false
positives. We then evaluated the robustness of IQS computed independently on the two
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halves of the data. In both European Americans and African Americans the correlation
was > 0.99 demonstrating that a database of IQS values from common imputations could
be used as an effective filter to combine data genotyped on different platforms.

IQS effectively differentiates well-imputed and poorly-imputed SNPs. It is particularly
useful for SNPs with low minor allele frequency and when datasets are genotyped on
different platforms.

17

INTRODUCTION
Genome-wide association studies (GWAS) represent a powerful approach to the
identification of genetic variants involved in common human diseases[32]. GWAS use
commercial SNP microarrays to genotype large numbers of genetic markers. However,
SNP microarrays currently can only genotype up to one million of the 9–10 million
common SNPs in the assembled human genome [7]. In addition, for a typical casecontrol design, several thousand cases and several thousand controls may be needed for
adequate power to detect associations[33]. With little cost, imputation can boost power
both by increasing SNP coverage and by combining samples from similar studies. Based
on haplotypes from the International HapMap project[14], imputation infers untyped
variants from known genotypes. The inference uses one of several model-based methods,
and the resulting imputed SNPs can be tested for association with a phenotype [34]. The
power of this method has been demonstrated in the literature where several groups have
found novel causal genes [35-38].

There are two situations where researchers avoid imputation due to increased error in
imputation: (1) SNPs with minor allele frequency less than 1% [4, 35, 39], and (2)
association studies where cases and controls are genotyped on different platforms.
Imputation accuracy, calculated for each SNP as the proportion of genotypes correctly
classified, is the gold standard for evaluating the quality of imputation. Unfortunately, it
is an inadequate filter in both of these circumstances. For the majority of SNPs,
imputation programs such as IMPUTE [34], MACH[39], and BEAGLE[40], have very
high imputation accuracy [34, 40-42]. However, the use of imputation accuracy in low
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frequency SNPs to evaluate imputation quality can be misleading. When the minor allele
frequency of a SNP is less than 5%, a program could randomly assign the two alleles to
the sample only using the minor allele frequency and achieve more than 90% accuracy.
Although SNPs with low minor allele frequencies (MAF<5%) are referred to as
uncommon SNPs, they represent more than 30% of SNPs in the HapMap Phase II CEU
population, and this proportion is even higher in African populations[7]. This problem
assessing imputation accuracy in lower frequency SNPs means that a large part of the
genome will not be adequately interrogated using imputation.

The second problematic situation for imputation is where cases and controls are
genotyped on different platforms. This is problematic because imputation error can vary
between cases and controls, causing increased rates of false positives in association
studies. There is no known method for effectively filtering the poorly imputed SNPs from
the well imputed SNPs on different platforms. Although this situation has been avoided
by researchers, it is an important application. Large studies such as Wellcome Trust and
the NIMH GAIN samples use common controls that could be used in other studies to
gain power [32, 43]. But, if the primary datasets were genotyped on a different platform,
imputation is necessary.

In order to assess the reliability of imputation with an emphasis on the less common
SNPs and an interest in evaluating data imputed from different platforms, we introduce a
new statistic, the imputation quality score (IQS). Partly motivated by Cohen’s statistic
Kappa to quantify rater agreement[44], IQS takes chance agreement into account and
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thus controls for allele frequencies. In this paper, we introduce IQS, demonstrate its value
in situations of low minor allele frequencies, and demonstrate how it can be used to
improve the type I error rate when cases and controls are genotyped on different
platforms.
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MATERIALS AND METHODS
Ethics statement
De-identified data from the Study of Addiction: Genetics and Environment (SAGE) were
analyzed for the research reported in this manuscript. SAGE consists of existing data
from three genetic studies of addiction: the Collaborative Study on the Genetics of
Alcoholism (COGA), the Collaborative Genetic Study of Nicotine Dependence
(COGEND), and the Family Study of Cocaine Dependence (FSCD). All participants in
COGA, COGEND and FSCD provided written informed consent for genetic studies and
agreed to share their DNA and phenotypic information for research purposes. The
institutional review boards at all data collection sites granted approval for data collected
from COGA, COGEND and FSCD to be used for the Study of Addiction: Genetics and
Environment. Specifically, approval was obtained from the Washington University
Human Research Protection Office (for COGA, COGEND and FSCD), the State
University of New York Downstate Medical Center Institutional Review Board (COGA),
the University of Connecticut Health Center Human Subjects Protection Office (COGA),
the Indiana University Research Compliance Administration (COGA), the University of
California, San Diego Human Research Protections Program (COGA), the Howard
University Institutional Review Board (COGA), The University of Iowa Human Subjects
Office (COGA), and the Henry Ford Health System Institutional Review Board
(COGEND). The second dataset was obtained from the National Institute of Mental
Health Center for Collaborative Genetic Studies on Mental Disorders
(http://www.nimhgenetics.org/) and was also de-identified.
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Methods
The computation of IQS requires the posterior probabilities of AA, AB and BB as output
by the imputation program. For one SNP genotyped on N individuals, the probabilities
can be readily tabulated into a 3 × 3 table where each cell, nij, represents the number of
individuals with true genotype i and imputed genotype j (Table 2.1). Note, in this
scenario, nij may not be an integer due to imputation probabilities being reported rather
than imputed genotypes.

We define the observed proportion of agreement (Po) as:

∑

Po

i

nii

n..

The observed proportion of agreement can be used to evaluate imputation reliability. But,
like imputation accuracy and average maximum posterior probability, it can overestimate
reliability for uncommon SNPs because it is not adjusted for “chance” agreement.

IQS adjusts for allele frequency by subtracting “chance” agreement from the “observed”
agreement. Similar to Po, “chance” agreement (Pc) is computed as the sum of the
products of marginal frequencies that would occur if genotypes are called at random
using the same marginal rates:

Pc

∑

i

ni.n.i

n..2
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IQS is then computed by subtracting the chance agreement from the observed agreement
and dividing by the maximum possible value of the numerator. The value of one indicates
a perfect match, and negative values indicate that the imputation program performed
worse than chance.

IQS

Po  Pc
1  Pc

In addition, the calculation of IQS can be expanded to evaluate non-random error. When
cases and controls are genotyped on different platforms (e.g., cases genotyped on the
Affymetrix array and controls genotyped on the Illumina array), some SNPs are not
genotyped in either array but are imputed from their respective arrays. This imposes nonrandom errors on the imputed genotypes. In particular, if we combine these imputed
genotypes together, it will inflate false positive rates. IQS can take this into account by
incorporating marginal frequencies into the calculation. For instance, if imputation from
the Illumina array reports that for a particular SNP, the probabilities of AA, AB and BB
are a1, a2, a3, and imputation from the Affymetrix array reports that the probabilities for
the three genotypes are b1, b2, b3, then nij in the calculation of Po becomes

nij

ai b j

In this scenario, IQS provides a useful criterion to exclude unacceptable SNPs imputed
from different sources.
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Data and imputation
The first dataset was collected as part of SAGE, one study in the Gene Environment
Association (GENEVA) project (http://genevastudy.org/). Samples were genotyped on
the Illumina Human 1M array at the Center for Inherited Disease Research (CIDR) at
Johns Hopkins University. The Illumina 1M array has a total of 1,049,008 probes as SNP
assays. All SNPs with a genotype call rate <98% were removed, as were SNPs with a
Hardy-Weinberg exact p value <1x10-4. Additional data cleaning procedures were
applied to ensure the highest possible data quality, including using HapMap controls,
detection of gender and chromosomal anomalies, hidden relatedness, population structure,
batch effects, Mendelian error detection, and duplication error detection[23]. The
composition of the remaining project samples in terms of self-identified ethnicity is 2597
European Americans and 1264 African Americans, confirmed by principal component
analysis. Among the 1,049,008 SNPs, 948,658 SNPs (90%) passed data cleaning
procedures.

The second dataset consists of controls from the National Institute of Mental Health
Center for Collaborative Genetic Studies on Mental Disorders
(http://www.nimhgenetics.org/). A total of 418 subjects (controls) were genotyped using
both the Affymetrix GeneChip Mapping 500K Array Set and the Illumina HumanHap
550K Array set and passed all cleaning procedures. All individuals in this study were
European Americans with no evidence of heterogeneity, verified by principal component
analysis[45]. All SNPs with a genotype call rate <95% were removed, as well as SNPs
with a Hardy-Weinberg exact p value <1x10-5. After quality control, 447,250 autosomal
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SNPs were retained from the Affymetrix 500K array, and 527,095 autosomal SNPs were
retained from the Illumina 550K array.

Imputation from each array to Hapmap SNPs was done by the program IMPUTE
(https://mathgen.stats.ox.ac.uk/impute/impute_v0.5.html) [34]. European Americans
were imputed using the CEU reference panel (HapMap release 22 - NCBI Build 36
dbSNP b126). African Americans were imputed separately using the YRI reference panel
(HapMap release 22 - NCBI Build 36 dbSNP b126). We omitted sex chromosomes in
this study because of the complication of imputation on these chromosomes. The
Illumina 1M array contains a small number of strand-ambiguous A/T C/G SNPs.
Although Illumina provides strand information about those SNPs, we still found a few
inconsistencies compared with the reference panel. In order to make sure that all SNPs
were reported on the same strand, all strand-ambiguous A/T and C/G SNPs (5583 in total,
0.5% of all Illumina 1M SNPs) were excluded from the comparison.
Imputation efficiency is calculated as the proportion of genotypes that had a maximum
posterior probability greater than 0.9, as recommended by IMPUTE.

Association tests were done by the program SNPTEST with the “-proper” option[34].
With this option, SNPTEST runs a logistic regression based on the probability of
genotype rather than dichotomous genotype, allowing the uncertainty of the imputation to
be factored into the consideration [46].
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Statistical estimates of imputation quality
Both IQS and imputation accuracy compare true genotypes to imputed genotypes. Given
that imputation is designed to infer unknown genotypes, one purpose of this paper was to
use IQS to evaluate statistics that measure the quality of imputation without knowing the
true genotype. The two statistics most commonly used for this purpose are the variance
ratio (rsq_hat in MACH)[39] and the imputed information score (PROPER_INFO in
SNPTEST) [34]. The variance ratio for a particular SNP is a ratio of the empirically
observed variance (based on the imputation) to the expected binomial variance p(1-p),
where p is the minor allele frequency[46]. As the amount of information available to
impute the SNP decreases, the empirically observed variance decreases and the variance
ratio approaches zero. The product of the variance ratio and sample size defines the
‘effective sample size’. Similarly, the imputed information score is a measure of
genotype information content, which is related to the effective sample size (power) for
the genetic effect being estimated [32, 34, 46]. Although computed using a different
approach, the information score is analogous to the variance ratio. For example, a SNP
with an imputed information score of 0.75 indicates that the imputed SNP genotypes are
equivalent to a dataset with 75% of the full sample size with precisely known genotypes.
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RESULTS
The Illumina 1M array covers all of the SNPs on the Illumina 550K array. We started
with all SAGE subjects genotyped on the Illumina 1M array and extracted the 545,966
SNPs that are present on the Illumina 550K SNPs. We used these Illumina 550K SNPs to
impute to the full Illumina 1M array. We imputed 262,864 autosomal SNPs in 2597
European Americans (EA), and 304,425 autosomal SNPs in 1264 African Americans
(AA). We compared imputed SNPs to the genotyping results from the Illumina 1M array.
The remaining SNPs could not be evaluated due to the absence of those SNPs in either
the Illumina 1M array or reference panel.

The imputation results are given in Table 2.2. The mean IQS is lower than the mean
accuracy in both EA and AA. There are cases where IQS is negative, indicating that
imputation did worse than chance in assigning genotypes. In this situation, 95% of the
minor allele frequencies lie between 0 and 0.058, 95% of the chance agreement rates lie
between 0.78 and 1, and the imputation accuracy is below chance agreement with 95% of
the values between 0.81 and 1. These are strong examples of how imputation accuracy
can be misleading when “chance” contributes so strongly to the proportion of agreement.

A second notable result is that the quality of imputation in AA is markedly lower than in
EA. This is seen in the decreased efficiency by nearly ten percentage points, and decrease
in mean IQS by nearly twelve percentage points. This is likely due to two factors. First,
African Americans have more diverse haplotypes and more uncommon alleles. Second,
there is non-negligible difference between African Americans and the YRI reference
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panel, which was clearly reflected by Eigenstrat population structure analysis [45].
Interestingly, imputation accuracy is nearly the same for EA as for AA, again
highlighting how imputation accuracy can overestimate the quality of imputation.

The relationship between IQS and imputation accuracy with respect to minor allele
frequency is seen in Figure 2.1. Although imputation accuracy increases with decreased
minor allele frequency, IQS drops dramatically with decreased minor allele frequency.
Because it is known that low minor allele frequency decreases the quality of imputation,
many studies drop SNPs with minor allele frequency less than 1%. According to this plot,
this practice would still retain SNPs with an average IQS score of 88%, and would
eliminate some well-imputed SNPs.

We then evaluated the effectiveness of IQS in the situation where cases and controls are
genotyped on different platforms. We randomly divided the SAGE data into two
subgroups labeled “cases” and “controls”. In “cases”, original genotypes were retained
for SNPs on the Illumina 550K array; and then imputation was performed to obtain the
full Illumina 1M array. In “controls”, original genotypes were retained for all SNPs on
the Illumina 1M array. This process is equivalent to combining cases genotyped by the
Illumina 550K array and controls genotyped by the Illumina 1M array.

We tested genetic association of all the 1M SNPs with the cases and controls. A QuantileQuantile Plot (Q-Q plot) is shown in Figure 2.2. By comparing the distribution of
observed P values against the theoretical model distribution of expected P values, Q-Q
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plots are used in genome wide association studies to assess the inflation of false positive
rates [47]. In randomized data without type I error arising from population stratification
or some other artifact, the Q-Q plot should be a 45 degree line. To ensure that our random
division of the data did not result in population stratification, we constructed a Q-Q plot
based on the true genotypes, which was normal as expected (λ=1.03) (Figure 2.2 A).
However, the Q-Q plot of imputed SNPs compared to genotyped SNPs is greatly
distorted (λ=1.15), suggesting that combining imputed SNPs with genotyped SNPs
without other quality control is problematic (Figure 2.2 B). Therefore, the observed
distortion was due to imputation error and the statistically skewed SNPs (Figure 2.2 B)
are false positives. We then filtered the imputed data by removing all SNPs with IQS ≤
0.9, retaining 76% of the imputed SNPs, and dramatically improving the Q-Q Plot
(λ=1.04) (Figure 2.2 C). The Q-Q plot remained grossly distorted even when the filter
was changed to an imputation accuracy of > 99%, retaining 72% of the SNPs, although λ
improved to 1.05 (Figure 2.2 D). Although this is a very strict value for imputation
accuracy, the Q-Q plot clearly shows there is significant type I error.

A more practical way of evaluating this approach is to look at the false positive rate.
Specifically, although no SNPs are associated with case/control status based on the true
genotypes, there were 4016 imputed SNPs that reach genome-wide significance (p<5×108

). The IQS filter >0.9 eliminated all the false positive SNPs, but the imputation accuracy

filter >0.99 still retained 759 false-positive SNPs. Based on these results, IQS is better for
discriminating between well-imputed SNPs and poorly-imputed SNPs.
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Although IQS can serve as an effective filter to minimize the use of poorly-imputed SNPs,
the computation of IQS requires a sample that was both imputed and genotyped for the
SNPs of interest. This is impractical in most situations. A secondary goal of this paper is
to determine whether there are ways to evaluate imputation quality without knowing the
true genotypes.

The two common methods for filtering imputed data are to combine a minor allele
frequency threshold with either the imputed information score >0.3 ~ 0.5
(PROPER_INFO in SNPTEST) [39, 46, 48-50] or the variance ratio >0.3 (rsq_hat in
MACH) [36, 39, 48-53]. We calculated these two statistics for our data and compared
these filters to IQS (Table 2.3). After filtering by these statistics, the type I error inflation
decreases. In the AA sample, IQS also acts as an effective filter and can be cautiously
approximated by a combination of MAF and either the imputed information score or the
variance ratio (Table 2.4). Unfortunately, even in the most conservative situation, over
three thousand false positives remain. Therefore this is an ineffective approach for
filtering poorly-imputed SNPs.

Filtering on MAF differences between the Hapmap and the study genotypes is another
possible approach to control false positives. In Table 2.3 and Table 2.4, we provided
results filtered by MAF difference at 0.01, 0.1 and 0.2 for European Americans and
African Americans, respectively. Filtering by MAF difference of 0.01 resulted in a
reduction of false positives, but retained less than 25% of the SNPs. In contrast, filtering
with a MAF difference of 0.1 or 0.2 retained many false positives.
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A second method for using IQS without directly genotyping would be to develop a
database of common imputations in common populations that records IQS scores for each
SNP. To test the practicality of this approach, we randomly divided the data into two
groups and tested the robustness of the IQS score for the SNPs imputed from the Illumina
550K array to the Illumina 1M array in both EA and AA. Because small changes in the
denominator of IQS (1-Pc) will dramatically affect the value of the statistic when MAF is
small, we included only SNPs with MAF>0.01. Figure 2.3 plots the IQS scores in both
populations. The correlation in EA is 0.99519 and the correlation in AA is 0.99020,
indicating that IQS is robust for the same imputation in a relatively homogeneous
population.

We further tested whether the set of hard-to-impute SNPs compiled from the first group
can be used to filter the imputed data in the second group. We applied a similar procedure
as in Figure 2.1. We randomly divided the second group into cases and controls. Cases
were genotyped on the Illumina 550K array and the remaining Illumina 1M SNPs were
imputed. Controls were genotyped on the Illumina 1M array. Figure 2.4 shows that the
QQ plot can be adjusted to normal by IQS calculated from the first group. This implies
that the development of a database of IQS scores for standard imputations would allow
researchers to use data genotyped on different platforms and filter out potential false
positives.
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In order to confirm these results in a different dataset, we replicated the study in
European American subjects genotyped on two different platforms, Affymetrix 5.0 array
and Illumina 550K array. All subjects were controls from the National Institute of Mental
Health Center for Collaborative Genetic Studies on Mental Disorders. We randomly
divided about 400 individuals into two subgroups labeled “cases” and “controls” in a
similar manner as above. “Cases” were genotyped by the Affymetrix 5.0 array and
“controls” were genotyped by the Illumina 550K array. In the replication, we also
expanded our investigation to include those SNPs that were not genotyped in either array,
but were imputed from their respective arrays. In fact, we had genotype data from both
platforms. No genome wide significant SNPs were found. Therefore, if there were any
significant SNPs in this simulation, they should be false positives. The result was similar
with inflation of Type I error that is effectively filtered by IQS, whereas filtering by MAF
and either the imputed information score or the variance ratio continue to have many
false positive values (Table 2.5).
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DISCUSSION
There are two situations in which imputation is avoided[46]: (1) SNPs with low minor
allele frequency and (2) cases and controls genotyped on different platforms. The
statistics previously used for measuring the accuracy of imputation are inadequate for
evaluating the quality of imputation due to their dependence on marginal SNP frequency.
Specifically, imputation accuracy, a measure of the concordance rate between the
imputed and observed genotypes for each SNP, dramatically over-estimates reliability
when minor allele frequencies are low and does not address the inflation of false positive
rates arising from imputation error due to random agreement. We developed IQS to more
precisely estimate imputation error, effectively filtering imputation error in these two
problematic situations. We showed that IQS is a more appropriate measure to evaluate
imputation reliability because it adjusts for “chance” agreement, and filtering by IQS
eliminates the inflation of the false positive rate arising from imputation error.

It is important to note that the traditional genome inflation factor λ is not an ideal
indicator of potential problems related to imputation quality. In our studies, we noticed
that λ is not dramatically different from 1, in contrast to the extent that the Q-Q plot is
distorted (Figure 2.2 B D). The reason is that λ reflects systematic inflation on all SNPs
while the distortion of the Q-Q plot in our studies is due to a small number of poorlyimputed SNPs. However, problems with this limited number of SNPs (less than 0.5% of
total SNPs) can be dramatic and lead to pronounced false positive P values that exceed
genome wide significance.
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We also would like to emphasize that we are dealing with the extreme situation when
cases and controls are genotyped on different platforms. The elevated false positive rates
are not explicitly reported in the literature, as most groups do not have this problem
because of the study design. But many groups have noticed it. In a recent paper by de
Bakker[46], the author noted “the dangers of combining cases genotyped on one platform
and controls genotyped on another” (Page 124). In the GENEVA consortium, there is a
consensus that genotypes imputed from one array should not be combined with imputed
genotypes from another array.

The reasons for the false positives are very complicated. Among the 4016 genome wide
significant SNPs, most of them have low R square with other available SNPs. It is
difficult to correctly assign their values based on related haplotypes, and they therefore
tend to receive the allele frequency from the reference panel.

Filtering by the difference between the reference and the estimated minor allele
frequency can effectively remove some genome wide significant SNPs. Of the 4016
genome wide falsely-significant SNPs, 3120 (77.7%) SNPs are removed by removing
those SNPs whose minor allele frequency difference is greater than 0.01.However, there
are still 832 (21% of the 4016 SNPs) that have passed the filter. Most of the 832
remaining SNPs share one character: they tend to have very low minor allele frequency
(MAF median =0.00096). Imputation tends to over-assign the major genotype to the
imputed SNPs, resulting in different allele frequency and therefore inflating the P value.
However, to filter by MAF difference at 0.01 is not an acceptable option. Most SNPs are
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correctly predicted even if the minor allele frequency is different. When we tried to
remove all SNPs whose minor allele frequency difference was greater than 0.01, 583,456
of the total 788,944 available SNPs (74%) were removed. Most of these SNPs were
correctly predicted even if minor allele frequency was different. This is because
imputation does not assign predicted genotype based on minor allele frequency, but
rather on haplotype modeling.

The typical methods for filtering poorly-imputed SNPs are using either the variance ratio
or the imputed information score combined with minor allele frequency. Imputation
quality is especially important in a study that combines genotypes from different
platforms. Therefore, we increased our thresholds for variance ratio and the imputed
information score in Table 2.3, Tables 2.4 and 2.5. But these measures were ineffective
in this extreme situation. However, IQS may be used as an effective filter to combine
data genotyped on different platforms.

Because IQS requires direct genotyping for evaluation, it is not a practical statistic for
directly evaluating imputation in the case where imputation is used to screen for
associations as a proxy for genotyping. However, IQS was shown to be a robust measure
of imputation for specific imputations (from one standard platform to another) and within
a broad population (tested in both EA and AA).

Generally speaking, different populations have different linkage disequilibrium structures
and different allele frequencies that lead to different IQS values. A mixture of different
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populations will make the IQS sensitive to the ratio of population mixture. Therefore, as
in general association studies, a mixture of different populations should be avoided.
However, African Americans have a unique and relatively stable genetic structure. The
IQS score from African Americans is stable in our study and is useful to filter out poorly
imputed SNPs.

Based on this theory, a database can be constructed and used to filter future imputations
and to avoid false positive associations. In order to advance the development of this
database, we have posted IQS scores for imputation from Illumina 550K to Illumina 1M
for CEPH on the website of the NIMH Center (http://www.nimhgenetics.org/). We
envision this as a dynamic database to be updated when new datasets include subjects
genotyped on multiple platforms. We will further provide IQS scores for various array
combinations when the genotype data of 6,000 controls typed on both the Affymetrix
6.0 and Illumina 1M array are available in the near future [24]. The future database will
include IQS scores for the following imputations: (1) from Affymetrix 6.0 to Illumina 1M,
(2) from Illumina 1M to Affymetrix 6.0, (3) from Illumina 300K to Affymetrix 6.0 plus
Illumina 1M, (4) from Illumina 550K to Affymetrix 6.0 plus Illumina 1M, and (5) from
Affymetrix 5.0 to Affymetrix 6.0 plus Illumina 1M. Although genotyping will be
ultimately required to confirm associations, using IQS as a filter will decrease the amount
of false positive findings that arise, making follow up of positive associations practical.

As genome wide association studies move toward rare variants, over-estimation of the
quality of imputation due to chance concordance of uncommon alleles will be more
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common. In addition, imputation will and should be used to analyze increasingly
complex data structures. IQS can be used as an accurate evaluation of imputation quality
enabling researchers to examine low allele frequencies and complex data structures.
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AB

n12
n22
n32
n.2

AA

n11
n21
n31
n.1

n13
n23
n33
n.3

BB

True genotypes

n1.
n2.
n3.
n..

Total
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IQS adjusts for minor allele frequency by comparing observed frequencies to expected frequencies.

Total

BB

AB

AA

Imputed
Genotypes

Table 2.1 - Marginal cross classification of the genotypes used for the computation of IQS

Imputation Quality Score (IQS)

Imputation Accuracy

Evaluation Measures

0.0~100.0
98.8~99.9
90.2
-9.1~100
90.7~99.2

Mean %
Range %
Inter-quartile %
Mean %
Range %
Inter-quartile %
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94.5
98.8

Efficiency %

260908

No. of imputed SNPs

European Americans

Table 2.2 - Summary of evaluation measures for European American and African American samples

68.4~94.3

-7.9~100

78.3

96.3~99.5

0.0~100.0

97.1

85.1

304425

African Americans

3093 (96.62%)
2726 (96.32%)
1392 (94.16%)
1869 (96.22%)
1226 (95.65%)
789 (94.57%)
498 (90.40%)
267 (22.89%)
2516 (95.11%)
2952 (96.57%)

Proper_info >0.5

Proper_info >0.7

Proper_info >0.9

Variance Ratio >0.3

Variance Ratio >0.5

Variance Ratio >0.7

Variance Ratio >0.9

MAF difference <0.01

MAF difference <0.1

MAF difference <0.2

2168 (89.42%)

1739 (87.97%)

120 (19.63%)

253 (85.00%)

514 (88.12%)

928 (88.89%)

1526 (89.27%)

1032 (87.67%)

2080 (89.28%)

2329 (89.48%)

2331 (89.48%)

Minor Allele frequency
>0.05
0 (83.90%)

1615 (77.38%)

1191 (75.94%)

76 (15.60%)

153 (74.14%)

390 (76.47%)

770 (77.04%)

1234 (77.33%)

805 (76.06%)

1571 (77.31%)

1775 (77.47%)

1775 (77.47%)

>0.10
0 (72.92%)
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The sample is based on 2,597 European Americans that were randomized to cases and controls. Cases used genotypes from the
Illumina 550K platform and were imputed to the 1M platform and controls were genotyped on the 1M platform. Genome-wide
significance is set as p<5×10-8. There were 792,563 SNPs available. False positives refer to the absolute number of SNPs that reached
genome-wide significance despite the filter. The retained percentage is the proportion of SNPs that passed the filter.

3120 (96.63%)

>0.01
0 (89.47%)

No filter

IQS > 0.9

False positives n (retained %)

Table 2.3 Comparison of empirical evaluations of imputation quality to IQS in European Americans

8620 (99.35%)
8087 (98.83%)
3715 (90.72%)
4728 (98.32%)
3059 (96.68%)
2092 (93.09%)
1518 (81.03%)
348 (14.05%)
6288 (90.53%)
8461 (99.22%)

Proper_info >0.5

Proper_info >0.7

Proper_info >0.9

Variance Ratio >0.3

Variance Ratio >0.5

Variance Ratio >0.7

Variance Ratio >0.9

MAF difference <0.01

MAF difference <0.1

MAF difference <0.2

7495 (90.57%)

5331 (81.89%)

241 (12.44%)

1020 (74.97%)

1570 (85,49%)

2524 (88.66%)

4185 (90.04%)

3243 (83.52%)

7254 (90.37%)

7665 (90.77%)

7671 (90.77%)

Minor Allele frequency
>0.05
1 (70.69%)

5363 (77.46%)

3227 (68.81%)

159 (9.97%)

557 (65.59%)

1054 (73.97%)

1976 (76.33%)

3530 (77.30%)

2058 (72.45%)

5205 (77.43%)

5537 (77.72%))

5537 (77.72%)

>0.10
1 (61.99%)
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Sample is based on 1264 African Americans that were randomized to cases and controls. Cases used genotypes from the
Illumina 550K platform and were imputed to the 1M platform and controls were genotyped on the 1M platform. Genome-wide
significance is set as p<5×10-8. There were 837,001 SNPs available. False positives refer to the absolute number of SNPs that
reached genome-wide significance despite the filter. The retained percentage is the proportion of SNPs that passed the filter.

8634 (99.35%)

>0.01
1 (76.82%)

No filter

IQS > 0.9

False positives n (retained %)

Table 2.4 - Comparison of empirical evaluations of imputation quality to IQS in African Americans

2 (80.52%)
0 (62.99%)
1550 (94.43%)
1300 (90.46%)
635 (77.49%)
1657 (95.40%)
1138 (92.43%)
729 (87.17%)
427 (73.31%)

IQS > 0.7

IQS > 0.9

Proper_info >0.5

Proper_info >0.7

Proper_info >0.9

Variance Ratio >0.3

Variance Ratio >0.5

Variance Ratio >0.7

Variance Ratio >0.9

318 (65.58%)

562 (77.90%)

904 (82.12%)

1285 (84.34%)

479 (70.43%)

1063 (81.23%)

1280 (84.12%)

0 (57.62%)

2 (72.78%)

63 (78.48%)

Minor Allele frequency
>0.05
1536 (85.55%)

257 (56.39%)

434 (66.93%)

673 (70.33%)

937 (72.05%)

338 (60.98%)

818 (69.74%)

979 (71.89%)

0 (49.87%)

2 (62.64%)

60 (67.30%)

>0.10
1107 (72.97%)
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Sample is based on 418 healthy European Americans from NIMH. Cases used genotypes from the Affymetrix 5.0 platform
and were imputed to the Illumina 550 platform and controls were genotyped on the Illumina 550 platform and imputed to the
Affymetrix 5.0 platform. Genome-wide significance is set as p<5×10-8. There were 2,553,465 SNPs available (including
Hapmap SNPs). False positives refer to the absolute number of SNPs that reached genome-wide significance despite the filter.
The retained percentage is the proportion of SNPs that passed the filter.

63 (87.5%)

>0.01
2047 (97.09%)

IQS > 0.5

No filter

False positives n (Retained %)

Table 2.5 - Comparison of empirical evaluations of imputation quality to IQS in combining Affymetrix 5.0 and Illumina
550K SNPs
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IQS adjusts for chance agreement. As the minor allele frequency approaches 0, the difference between IQS and imputation
accuracy increases. The standard deviation is shown for every other point.

Figure 2.1 - The means of IQS and imputation accuracy within each minor allele frequency interval

Figure 2.2 - The Q-Q plots based on randomly dividing data into cases and controls

Samples were divided randomly into cases and controls. (A) All Illumina 1M SNPs are
directly genotyped indicating there is no population stratification or other non-random
factors in cases and controls. (B) Cases were genotyped on the Illumina 550K array and
the remaining Illumina 1M SNPs were imputed. (C) An IQS filter (IQS>0.9) was applied,
retaining 92% of the SNPs. (D) An imputation accuracy filter (>0.99) was applied,
retaining 91% of the SNPs.
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Figure 2.3 - Evaluation of the robustness of IQS score

European Americans (A) and African Americans (B) datasets were split in half and
Illumina 550K SNPs were imputed to Illumina 1M SNPs. IQS score for the two halves of
the data were plotted against each other. SNPs with minor allele frequency less than 0.01
were excluded to avoid zero in the denominator.
45
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The set of hard-to-impute SNPs compiled from one dataset can be used to filter the imputed data in another dataset. (A) Cases were
European Americans genotyped on the Illumina 550K array and the remaining Illumina 1M SNPs were imputed. Controls were
European Americans genotyped on the Illumina 1M array. The QQ plot was shown for the 790,965 available SNPs. (B) An IQS filter
(IQS>0.9) was applied, retaining 92% of the SNPs. IQS was calculated from an independent dataset. (C) A similar QQ plot for
African Americans. Cases were genotyped on the Illumina 550K array and the remaining Illumina 1M SNPs were imputed. Controls
were genotyped on the Illumina 1M array. The QQ plot was shown for the 836,993 available SNPs. (D) An IQS filter (IQS>0.9) was
applied, retaining 78% of the SNPs. IQS was calculated from an independent dataset.

Figure 2.4 - A database of IQS can be used to filter poorly-imputed SNPs

Chapter 3: Copy Number Variation Accuracy in Genome Wide Studies

*

This chapter is adapted from: Lin P et al. (2011) Copy Number Variation Accuracy in
Genome Wide Studies. Human Heredity. In Press
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ABSTRACT
Copy Number Variations (CNVs) are a major source of variation between individuals and
are a potential risk factor in many diseases. Numerous diseases have been linked to
deletions and duplications of these chromosomal segments. Data from genome-wide
association studies (GWAS) and other microarrays may be used to identify CNVs by
several different computer programs, but the reliability of the results has been questioned.

To help researchers reduce the number of false positive CNVs that need to be followed
up with laboratory testing, we evaluated the relative performance of CNVpartition,
PennCNV and QuantiSNP, and developed a statistical method for estimating sensitivity
and positive predictive value of CNV calls and tested it on 96 duplicate samples in our
dataset.

We found that the positive predictive rate increases with number of probes in the CNV
and the size of the CNV, with the highest positive predicted rates in CNVs of at least
500kb and at least 100 probes. Our analysis also indicates that identifying CNVs reported
by multiple programs can greatly improve the reproducibility rate and the positive
predicted rate.

Our methods can be used by investigators to identify CNVs in genome-wide data with
greater reliability.

48

INTRODUCTION
Copy Number Variations (CNVs) are duplications or deletions of a particular segment of
an individual’s genome. Over the past 10 years, evidence has accumulated that CNVs
play an important role in disease [13-19]. It is hypothesized that a CNV changes the
expression level of genes in or near those regions, leading to various phenotypes,
including disease[12]. Therefore, CNVs constitute a major source of inter-individual
variation that could contribute to common disorders and complex traits[54]. The advent
of genome-wide association studies (GWAS) has led to the possibility of discovering
CNVs across the genome. So far, many CNV detection programs have been developed
for this purpose, including CNVpartition, PennCNV, and QuantiSNP.

However, despite the obvious scientific importance of understanding the role that CNVs
play in human disease, there is some controversy regarding the use of GWAS data to
detect CNVs. First, a recent study suggested that disease-related CNVs detected from
GWAS data are well tagged by SNPs, and, therefore, CNVs do not add further
information[55][55][55][55][55][55]55(Rice, Rochberg et al. 1992). Second, there is
evidence that different methods for identifying CNVs from GWAS data report different
results, even when applied to the same array data[56].

To address the first controversy, although many common CNVs that are well-typed in a
microarray can be tagged by SNPs[55][55][55][55][55][55]55(Rice, Rochberg et al. 1992),
there are at least three reasons why testing the association between a trait and CNVs
remains important. First, CNVs may be the true causative variant of the trait, and will
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therefore show a stronger association than a SNP tag. For example, the copy number of
the salivary amylase gene (AMY1) is correlated positively with salivary amylase protein
level[12]. Second, the number of common CNV loci is limited, and therefore, the typical
GWAS significance level of p<5x10-8 is overly conservative [57]. After adjusting for
multiple tests in GWAS, SNPs tagging associated CNVs are unlikely to be statistically
significant at this stringent threshold, although they would be significant in a setting
where only CNVs were tested. Third, de novo CNVs are not well-tagged by SNPs. In
addition, tagging a recurrent CNV by multiple SNPs demands heavy computation. Thus,
despite the potential for some CNVs to be tagged by SNPs, many researchers continue to
look for CNVs in GWAS data [58].

The second controversy with localizing CNVs is the imprecision of estimation.
Methodologies for measurement of CNVs in GWAS microarrays continue to evolve,
leading to the varied results mentioned above. Currently, most methods that make use of
SNP microarray data to detect CNVs depend on LogR ratio and b-allele frequency from
microarray data. One simple and straightforward method draws LogR ratio and b-allele
frequency as the Y axis and chromosome position as the X axis. When a deletion or
duplication occurs, the pattern of LogR ratio and b-allele frequency will change
accordingly [59]. However, this method requires extremely high data quality and
necessitates investigators spot pattern changes. Subsequently, more sophisticated
methods of identifying CNVs have attempted to adjust undesirable microarray artifacts,
such as genomic wave [60], and build a mathematical model to detect CNVs from those
data. Numerous programs have been written for this purpose. The most widely used are
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CNVPartition (http://www.illumina.com/software/illumina_connect.ilmn), PennCNV[28]
and QuantiSNP [61]. Although all three programs use standard statistics from the
observed data to estimate the location of CNVs, they use different iterative mathematical
methods. CNVPartition uses a likelihood-based algorithm, PennCNV implements a
hidden Markov model (HMM), and QuantiSNP uses an Objective Bayes Hidden-Markov
Model (OB-HMM). A detailed comparison of these different algorithms can be found in
Dellinger et al’ study[56]. These three programs have helped many studies find putative
disease-related CNVs[62-66]. Moreover, several recent studies have used SNP
microarray data to study the characteristics of CNVs[59, 67]. However, there is evidence
that the varied algorithms identify different CNVs even with the same data, questioning
the reliability of using these programs to detect CNVs [56].

Although laboratory confirmation is necessary to validate CNVs derived from SNP array
platforms[14, 57, 63-66], it is not economically feasible to validate all CNVs in a
genome-wide scale, especially for the purpose of estimating measurement accuracy. Here,
using duplicates in a GWAS sample, we develop an algorithm to better evaluate the
accuracy of CNVs predicted by several CNV calling algorithms for GWAS data.
Whether a CNV that is called the first time can be confirmed the second time is restricted
by sensitivity and specificity. This gives some insight about CNV calling accuracy to
investigators wishing to evaluate CNVs found in SNP microarray data that might be
associated with disease.
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METHODS
Data and quality control
The dataset was collected as part of the Study of Addiction: Genetics and Environment
(SAGE) [68]. SAGE is part of the Gene Environment Association Studies(GENEVA)
project (http://genevastudy.org/) [58]. All participants in SAGE provided written
informed consent for genetic studies and agreed to share their DNA and phenotypic
information for research purposes. The institutional review boards at all data collection
sites granted approval for the use of the data. In this study, all samples were de-identified
and only subjects who consented to health research were included.

Samples were genotyped on the Illumina Human 1M array at the Center for Inherited
Disease Research (CIDR) at Johns Hopkins University. The Illumina 1M array has a total
of 1,072,820 probes, of which 23,812 are “intensity-only”. Data cleaning procedures
included using HapMap controls, detection of gender mis-annotation and chromosomal
anomalies, cryptic relatedness, population structure, batch effects, Mendelian error
detection, and duplication error detection [23, 68]. In this study, 107 study subjects were
genotyped in duplicate on the Illumina 1M array. These subjects were selected randomly
from the study sample for the purpose of assessing genotyping accuracy. The mean of the
SNP calling discordance rate between the duplicates was 0.02%. These duplicates were
further compared against each other to determine the accuracy of CNV calling.
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CNV calling
We used three common programs to call CNVs: CNVPartition, PennCNV, and
QuantiSNP. We also implemented a procedure to adjust genomic waves when we called
CNVs by PennCNV and QuantiSNP[60]. Both PennCNV and QuantiSNP report data
quality control measures. In order to pass the quality control, a subject and its replication
need to be considered as good quality by both PennCNV and QuantiSNP. After quality
control, 96 subjects and their replications passed these filters. CNVpartition does not
provide any quality control information for individual subjects. We also removed all
CNV calls with Log Bayes Factor(LBF) less than 10, which is recommended by
QuantiSNP (See supplementary materials for more details).

PennCNV reports log R ratio standard deviation (LRR_SD), B allele frequency drift
(BAF_Drift) and waviness factor (WF) for quality control. We used the following criteria
to look for good samples (http://www.yale.edu/state/Pipeline.htm).
1. LRR_SD < 0.28
2. BAF_Drift <0.01
3. WF > -0.05 and < 0.05
If a subject satisfied these criteria, it was considered a sample with good quality.
Similarly, QuantiSNP reports B allele frequency outliers (BAFout), LogR standard
outliers (LogRout), B allele frequency standard deviation (BAFstd) and LogR standard
deviation (LogRstd) for each chromosome. The following criteria were used to determine
good quality.
1. BAFout ≤ 0.1

53

2. LogRout ≤ 0.1
3. BAFstd ≤ 0.2
4. LogRstd ≤ 0.4
For any subject, if one or more autosomal chromosomes did not satisfy these criteria, the
sample was considered poor quality.

In order to pass quality control, a sample and its replication had to be considered as good
quality by both PennCNV and QuantiSNP. After quality control, 96 subjects and their
replication data passed the filter. CNVpartition does not provide any quality control
information for individual subjects.

In these samples, we identified 2348 potential regions across the genome for deletions
and 851 potential regions for duplications. For any particular potential region, at least one
of these 96 subjects had a duplication or deletion in this region. We restricted our study to
only these potential regions.

Each program also reports a confidence score based on different mathematical models.
The confidence score is a positive number representing the likelihood that there is a CNV
at that region, with a higher number representing a greater probability of a CNV in that
region. The confidence scores for the three programs are calculated differently and are on
different scales. CNVPartition uses a likelihood-based method to compute the confidence
score (http://www.illumina.com/software/illumina_connect.ilmn). QuantiSNP computes
a Bayes Factor by comparing the evidence of the region containing deletions or
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duplications to that of having two copies, and reports the log of the Bayes Factor as the
confidence [61]. PennCNV reports an experimental confidence score that is not well
documented[28]. These confidence scores allow users to filter out CNV regions that are
likely to be false positives. Due to variability of the confidence score distributed among
the three programs, we converted the confidence scores within each program into
percentiles and used them as covariates for modeling.

Comparative statistics
These CNV calls are then compared against each other among duplicate samples.
Concordance is defined as the percentage of regions that have been consistent in the
existence or absence of CNVs between duplicate samples. However, this measure is
misleading, because a large percentage agreement is the chance agreement of negatives.

In addition to the concordance rate, we reported the reproducibility rate. We define a
CNV as being reproduced when the percentage of overlap of these two CNVs is greater
than 30% of the region where the two CNVs cover. The reproducibility rate is defined as,
the percentage of CNVs that can be reproduced at time point 2 among CNVs that are
discovered at time point 1.

Statistical modeling
Whether a CNV discovered at the first time can be confirmed at the second time is
restricted by sensitivity and specificity. In turn, this information can be used to estimate
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sensitivity and specificity. Using a model derived in previous work [55, 69, 70], we
calculated CNV sensitivity and positive predicted rate with logistic regression parameters
derived from CNV characteristics. All CNVs called by any program or more than one
program were used to fit the model. We also added the consistency rate--the number of
programs reporting a CNV at a particular locus--as a covariate. The mathematical model
allows us to estimate the cumulative probability of being true for a set of CNVs with
similar characteristics, and thus avoids the issue of testing whether a particular CNV is
true or not.

The model is derived from our previous work on psychiatric disorder diagnoses [55, 70].
For some psychiatric disorders, the symptoms are not stable, and similar to CNV calling,
the diagnoses may not be accurate. Whether a positive diagnosis at time point 1 can be
confirmed at time point 2 is determined by sensitivity and specificity. And this
information can be used to estimate sensitivity and specificity per se. Similarly in this
study, we used the result of CNV calling from replication samples to estimate sensitivity
and specificity. We realized that testing the validity of each CNV is unfeasible on a
genome wide scale. We therefore constructed a mathematical model to estimate the
probability of being true at a larger scale.

For the mathematical model, we defined the reproducibility as being reproduced by any
of the three algorithms; however, there are arguably several valid ways to do this. Some
may require a region shared by one, two, and all of the three algorithms. We decided to
calculate the maximum coverage of all available algorithms: it could be a direct report if
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only one algorithm was available, maximum coverage of two if two were available and
maximum coverage of three if three were available. Then we tested whether the shared
region of the maximum coverage was over 30% of the total coverage. We chose this
approach because: 1. this issue is overcomplicated and needs to be simplified, and 2. the
boundary of CNV is hard to define, thus any report may be treated as evidence of a CNV.

We modeled the positive predicted rate for duplication and deletion separately. We let T
denote true state and Oi denote observed state, at time i (i=1,2). T and Oi take the value 1
for “presence” and 0 for “absence” of CNVs (duplications or deletions). The sensitivity p
and specificity q are

p Pr(Oi 1| T 1)
q Pr(Oi

0|T

0)

Each CNV calling program typically reports a value for calling confidence. Let Z denote
a set of CNV characteristics, including percentile distribution of confidence scores from
each program and the number of programs that report a CNV at a particular CNV
segment. Let k denote the true base rate at this region. Therefore, we have

k Pr(T 1)
Then the probability of observing a CNV (duplication or deletion) at evaluation i is given
by
(1)

P

Pr(Oi 1| Z )

pk  (1  q)(1  k )

Similarly, the probability of observing a case at the second time, conditional on observing
a case at the first time at condition Z is
(2) Pr(O2 1| O1 1, Z )

p Pr(T 1| O1 1, Z )  (1 q)(1 Pr(T 1| O1 1, Z ))
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In order to estimate theoretical sensitivity for this model, we used the following
methodology. At time 2, the probability of confirming a true positive which is discovered
at time 1 (i.e. identifying a CNV in the second replicate, given that it is true and it was
seen in the first replicate) is the theoretical sensitivity of this model. Let Zmax denote the
theoretical condition for which all three CNV estimation programs asymptotically reach
the maximum value for prediction of a CNV. Then, we make the assumption that if a
CNV is identified (O1=1) with the theoretical maximum values of the three programs
(Zmax), then the CNV is a true positive (T=1):

Pr(T 1| O1 1, Zmax ) 1
This is a theoretical situation. Because we used percentile distributions of confidence
scores, Zmax should be 100 for each confidence score, and 3 for the consistence rate,
which are the theoretical maximum values that Zmax can reach. Combining

Pr(T 1| O1 1, Zmax ) 1 with Function (2), we have:
p Pr(O2 1| O1 1, Zmax )
where p is the theoretical sensitivity of our mathematical model. The value of

Pr(O2 1| O1 1, Z ) can be modeled by a logistic regression model because O2, O1, and Z
are all observed values:

Pr(O2 1| O1 1, Z ) 1/ [1  exp(D  E Z )]
The percentile of confidence scores from CNVpartition, PennCNV and QuantiSNP, as
well as the consistency rate, were all significant for duplications or deletions. Based on
the logistic regression and the formula p

Pr(O2 1| O1 1, Zmax ) , we estimated that the
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theoretical sensitivity is 0.91 for duplications, and 0 .97 for deletions. This is the
theoretical sensitivity for the mathematical model, and should be distinguished from the
sensitivity p’ for each subcategory. We also wanted to point out that these regions are
restricted to 851 potential regions for duplications and 2,348 potential regions for
deletions.

We have duplicate samples. The probability of observing a CNV (duplication or deletion)
at both times is given by

P

(3)

Pr(O2 1, O1 1| Z1 , Z 2 )

p 2 k  (1  q)2 (1  k )

Now, q can be solved by combining function (1) and (3),

q

p  P  P  pP
p  P

From this formula, we also can estimate that the theoretical specificity, which is 0.986 for
duplications and 0.989 for deletions.

For each CNV, by solving function (2), we can obtain the positive predicted rate R+,
which is the probability of being a CNV, conditioned on being positive at time 1.

R

Pr(T 1| O1 1, Z ) [Pr(O2 1| O1 1, Z )  q 1] / ( p  q  1)

R+ was calculated for all CNVs, and we took the mean value of R+ of CNVs within each
category. This is the positive predicted rate for each subcategory reported in Tables 3.23.5. And this value is later used to calculate the sensitivity for each subcategory as
described below. We assume p’, q’ are the sensitivity and specificity within each
subcategory, respectively, and k is the true base rate. We have
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(4)

P
R
k

p'

Functions (1), (3) and (4) together only have 3 unknown variables: k, p’ and q. P+ and
P++ can be obtained from the data directly. By solving functions (1), (3) and (4), we can
obtain the following formula for p’ .

ap '2  bp ' c 0
Among them,

a P R , b ( P  P R )2  P  P 2 R 2 , c

P R P

Finally,

p'

b  b2  4ac
2a

The negative root is ignored because it is out of boundary.
Given that p’ can be calculated from the function above, and both P+ and R+ are available,
we can also estimate the base rate k by solving function (4). Therefore, we have

k

P
R
p'

When all CNV callings are considered, the base rate k is 0.016 for deletions and 0.012
for duplications.

Based on this model, we estimated the probability that an observed CNV is a true positive,
and further the sensitivity for different methods. Duplications and deletions were
modeled separately. The percentile of confidence scores from CNVpartition, PennCNV
and QuantiSNP, as well as the consistency rate, were all significant for duplications or
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deletions, and thus were included in our model (See supplementary materials for more
details).

Model validation
In calculating the positive predicted rate R+, we assumed that Pr(T 1| O1 1, Zmax ) 1 ,
i.e., a theoretical CNV is true if three programs simultaneously report the highest
confidence scores. This assumption is only used to estimate the theoretical sensitivity of
our mathematical model. Zmax is the characteristic from a theoretical CNV that has the
highest confidence score and is confirmed by all three programs. Because we used
percentile distributions, the vector of Zmax includes 100 for each confidence score and 3
for the consistence rate. For a theoretical CNV like this, our mathematical model can only
capture part of it; therefore probability is the theoretical sensitivity of our mathematical
model. This theoretical CNV does not exist in reality. We can only test some CNVs with
weaker characteristics. Our rationale is that if a CNV with slightly weaker characteristics
can meet the requirement, a theoretical CNV with perfect characteristics can meet the
requirement as well. We tested CNVs with weaker characteristics on Chr 14 by qPCR.
Among them, 48 subjects have CNVs with R+ more than 0.91, with the average as high
as 0.98. The qPCR experiment confirmed that all 48 subjects were reported as having the
CNVs and 0 were false positive.

Based on our model, we were able to calculate the positive predicted rate for each CNV.
We grouped CNVs with similar positive predicted rates together and compared the
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positive predicted rate of each group against the proportion of CNVs from that group that
can be reproduced. We reported a CNV as reproduced in the duplicate if the CNV
detected by the two independent genotyping shares more than 30% of the total coverage.
We were able to obtain agreement between theoretical positive predicted rate and
experimental reproducibility in duplicates (Figure 3.1).

We also randomly selected 90% of replicate pairs, and randomly assigned status as
discovery or replication, and then we calculated the positive predicted rate for “any 1 of 3
programs” method. We repeated the process 100 times. The positive predicted rate was
stable across many repeats (Figure 3.2), indicating that our result is not subject to serious
random fluctuations.
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RESULTS
We tested the concordance rate of CNV calls from each program in duplicate samples.
The concordance rates for the three programs range from 98.0% to 99.3% (Table 3.1).
However, concordance rate is not a good indicator of CNV calling reliability, because the
concordance rate also includes the agreement of the absence of CNVs. Similar to SNPs
with very low minor allele frequencies [71], a large portion of agreement is due to the
chance agreement of negatives. Because of this, we believe that the reproducibility rate is
a more appropriate measure for CNV calling reliability. We reported a CNV as
reproduced in the duplicate if the CNV detected by the two independent genotyping
shares more than 30% of the total coverage. The reproducibility among deletions ranged
from 59% to 62%, and the reproducibility among duplications ranged from 43% to 57%
(Table 3.1). This highlights the variation between methods and the low reliability of all
three methods.

We then estimated the reproducibility rate, the positive predicted rate and the sensitivity
for each CNV calling method (Table 3.2). As expected, deletions have higher
reproducibility rates, higher positive predictive rates and better sensitivity. For both
duplications and deletions, the method that requires CNVs to be reported by all three
programs has the highest reproducibility rate and the highest positive predicted rate.

False CNV calling may be caused by intensity variation (noise) from the microarray. A
short CNV segment with few probes is particularly vulnerable to noise. Because of this,
we estimated both the reproducibility rate and the positive predicted rate R+ within four
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subcategories for each method based upon number of probes contained within the CNV
(Table 3.3). Some of these subcategories are often used in the literature as thresholds for
quality controls [28]. Not surprisingly, a higher positive predicted rate R+ was seen when
there were more probes in a single CNV. We also tested the relationship between the size
of CNV segments and positive predicted rate R+ (Table 3.5). As expected, the result was
similar to Table 3.3, because a larger CNV segment typically contains more probes.

The primary purpose of this study was to determine the reliability of CNVs found in
microarrays, such as in GWAS. We found that if a CNV is reported by at least 3 of 3
programs, it has the highest positive predicted rate. Moreover, in a microarray, probes are
not always evenly spaced. We hypothesized that the combination of the number of probes
and the size would boost the positive predicted rate. We tested this hypothesis by using
both the number of probes and the size as filters. The results suggest that a minimum of
10 probes and 10K base pairs are necessary to reach > 80% positive predicted rate (Table
3.4).
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DISCUSSION
Data from genome wide association studies can be used to estimate locations of CNVs
and their potential effects on disease. There is disturbing evidence that calling CNVs
from SNP microarray data is not reliable [56]. For this reason, investigators are interested
in quantifying the reliability. To our knowledge, this is the first study that compares
CNV calls from a considerable number of duplicate samples.

Although experimental validation is necessary for CNV association studies, it is both
demanding and costly and should be limited to regions most likely to contain true CNVs
associated with disease. In this study, we introduced a convenient way to identify
potential false positive CNVs on a genome wide scale, using an estimated positive
predicted rate for CNV callings. Our results confirmed that combining CNVs from
different programs is one way to improve the positive predicted rate.

In this study, we found that 10 probes and 10 kb in size maximize CNV calling quality.
We also discovered that deletions are much easier to detect than duplications. The reason
is that when calling genotypes from the microarray, one deletion represents a 50%
decrease in signal intensity, rather than the 33% increase caused by one duplication. In
addition, the B allele frequencies—a reported measure from microarray—of those SNPs
at a particular deletion region usually take the value of 0% or 100%, leading to a
distinctive pattern that is relatively easy to spot.
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Different methods for estimating the locations of CNVs use different mathematical
models. Both PennCNV and QuantiSNP use hidden Markov models [28, 61], while
CNVPartition estimates model parameters using bivariate Gaussian distributions. Each
method has its own strengths, but all also have relatively high frequencies of falsepositive CNVs. The “3 of 3” method, however, minimizes false positives.

When 3 different programs call the same CNV, different boundaries may be reported,
leading to a quandary on how to categorize this particular CNV. To resolve this, we
included all CNVs for one category if a CNV reported by any program satisfies the
category. Therefore, the total number of CNVs for “3 of 3 programs” may be higher than
the total number of CNVs reported by each program alone.

Moreover, the reproducibility in our manuscript is defined either as being reproduced by
itself or being reproduced by any of the three algorithms. The exact definition is indicated
below in Tables 3.1-3. 2. The reason for this is to address both self-reproducibility and
across-the-spectrum reproducibility. In Table 3.1, we adopted “being reproduced by itself”
as the criterion in order to show self reproducibility. That is because self reproducibility
is a good indicator of reliability when the truth is not known, and also a good point to
start with. The fact that a program cannot even reproduce its result is surely a good sign
of poor reliability. In Table 3.2, we want to compare the reproducibility among the three
algorithms and the three combinational methods, therefore, a consistent criterion, which
is across-the-spectrum reproducibility for this table, is needed in order to make the
comparison fair and meaningful.
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The sensitivity here is restricted to CNVs that can be detected by a microarray. In our
data from 96 replication subjects, we identified 2348 potential regions across the genome
for deletions and 851 potential regions for duplications. For any particular potential
region, at least one of these 96 subjects had a duplication or deletion in this region.
Among these regions, the true base rate k is 0.016 for deletions and 0.012 for duplications
(See the supplementary materials). We restricted our study only to these potential regions.
Some CNVs in the genome may be located at particular regions where no probes or very
few probes exist. Those CNVs can never be detected by microarray technology, and
therefore are excluded from the estimation of sensitivity. The sensitivity here may be
better understood as the sensitivity adjusted by the total number of those potential CNV
regions. Therefore, the sensitivity reported by our study should not be directly compared
to other studies [56, 72].

Based on our model parameters, investigators can estimate the probability that an
estimated CNV is true. Interested researchers can estimate the positive predicted rate for
their own data if confidence scores and some other information can be provided. Finally,
it is important to emphasize that there are benefits to be gained from utilizing multiple
CNV calling approaches and then comparing the results between them. This can
maximize the sensitivity for discovery, maximize the positive predicted rate for
verification, or balance the sensitivity and the positive predicted rate to a desired point.
As genome wide association studies move forward from SNPs to CNVs, investigators
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can better identify CNVs associated with human disease by using multiple estimation
programs and calculating the positive predictive rates of observed CNVs.
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99.3%

Deletion

b

Reproduced by CNVPartition
Reproduced by PennCNV
c
Reproduced by QuantiSNP

a

99.2%

Duplication
61%

54%

CNVPartition
Concordance rate Reproducibility ratea
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98.6%

98.0%
62%

41%

PennCNV
Concordance rate Reproducibility rateb
98.9%

98.9%

63%

48%

QuantiSNP
Concordance rate Reproducibility ratec

Table 3.1 - Concordance rate and reproducibility rate for CNVPartition, PennCNV and QuantiSNP

0.92

0.83

0.94

0.82

0.75

PennCNV

QuantiSNP

Any 1 of 3 Programs

Any 2 of 3 Programs

3 of 3 Programs

0.79

0.61

0.43

0.58

0.46

0.69

0.73

0.56

0.40

0.55

0.41

0.63

Duplication
Reproducibility
Positive predicted
rate*
rate R+
Sensitivity
p’
0.75
0.94
0.91
0.96
0.88
0.72

Total No.
of
CNVs
849
2001
1177
2199
1169
642
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*Reproduced by any one of the three programs: CNVPartition, PennCNV and QuantiSNP

0.77

Sensitivity
p’

CNVPartition

Method

0.89

0.76

0.59

0.69

0.65

0.78

0.85

0.75

0.59

0.68

0.64

0.77

Deletion
Positive predicted
Reproducibility
rate R+
rate*

Table 3.2 - Positive predicted rate R+ , sensitivity p’ and total number of CNVs for different CNV calling methods.

1816

3565

5767

4171

2348

2227

Total No.
of
CNVs

0.29 (1009)

0.42 (228)

0.65 (122)

PennCNV

QuantiSNP

3 of 3 programs
0.77 (461)

0.57 (757)

0.56 (930)

0.69 (486)

0.87 (157)

0.70 (163)

0.88 (117)

0.77 (143)

Duplication
10-50
50-100

0.91 (83)

0.84 (77)

0.95 (39)

0.88 (84)

≥100

0.84 (993)

0.63 (2411)

0.58 (3433)

0.70 (1176)

<10

0.92 (1013)

0.74 (1644)

0.81 (1334)

0.85 (974)

10-50

0.96 (101)

0.74 (178)

0.95 (74)

0.87 (82)

Deletion
50-100

0.98 (67)

0.89 (81)

0.99 (45)

0.88(54)

≥100
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The total number of CNVs is indicated in parentheses. In calculating the total number of CNVs, we included a CNV for a certain category if the report from any
one of the specified programs’ satisfied this category.

0.54 (150)

<10

CNVPartition

No. of Probes

Table 3.3 - The positive predicted rate R+ within subcategories defined by the number of probes

---

---

---

10-50

50-100

>100

---

---

0.72 (20)

0.68 (39)

1-10kb

0.79 (2)

0.89 (19)

0.79 (250)

0.64 (81)

0.96 (29)

0.91 (73)

0.74 (239)

0.62 (6)

Duplication size
10-100kb
100-500kb

0.90 (56)

0.82 (74)

0.72 (20)

---

≥500kb

---

---

---

0.80 (47)

<1kb

---

---

0.91 (144)

0.83 (595)

1-10kb

0.99 (3)

0.95 (39)

0.93 (731)

0.84 (426)

Deletion size
10-100kb

0.99 (32)

0.98 (45)

0.91 (247)

0.76 (9)

100-500kb

0.97 (37)

0.96 (24)

0.86 (24)

---

≥500kb
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The total number of CNVs is indicated in parentheses. In calculating the total number of CNVs, we included a CNV for a certain category if the report from any
one of the specified programs’ satisfied this category.

0.58 (3)

<1kb

<10

No. of Probes

Table 3.4 - The positive predicted rate R+ for the “3 of 3 method”

0.46 (4)

0.26 (39)

0.30 (8)

0.58 (3)

CNVPartition

PennCNV

QuantiSNP

3 of 3 programs

0.69 (56)

0.47 (91)

0.31 (428)

0.54 (75)

1-10kb

0.77 (322)

0.57 (515)

0.43 (1076)

0.68 (360)

Duplication
10-100kb

0.78 (311)

0.60 (442)

0.60 (478)

0.72 (300)

100-500kb

0.83 (114)

0.64 (161)

0.78 (79)

0.77 (120)

≥500kb

0.80 (47)

0.41 (305)

0.51 (191)

0.63 (57)

<1kb

0.84 (690)

0.68 (1505)

0.60 (2229)

0.72 (784)

1-10kb

0.90 (1075)

0.74 (1745)

0.69 (2091)

0.80 (1115)

Deletion
10-100kb

0.93 (304)

0.67 (623)

0.86 (342)

0.85 (255)

100-500kb

0.94 (79)

0.69 (141)

0.97 (29)

0.88 (64)

≥500kb
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The total number of CNVs is indicated in parentheses. In calculating the total number of CNVs, we included a CNV for a certain category if the report from any
one of the specified programs’ satisfied this category.

<1kb

Size

Table 3.5 - The positive predicted rate R+ within subcategories defined by size

Figure 3.1 - The relationship between positive predicted rate and reproducibility
rate in duplicate samples

74

Figure 3.2 - The positive predicted rate is stable across many replications
A

B

We randomly selected 90% of replicate pairs, and randomly assigned status as discovery
or replication, and then we calculated the positive predicted rate for “any 1 of 3 programs”
method. We repeated the process 100 times. The positive predicted rate fluctuates in a
narrow range for duplications (A) and deletions (B).
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Chapter 4: CNVs and Alcohol Dependence

*

This chapter is adapted from: Lin P et al. Copy number variations in 6q14.1 and 5q13.2
are associated with alcohol dependence. In Preparation.
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ABSTRACT
Excessive alcohol use is the third leading cause of preventable death and is highly
correlated with alcohol dependence, a heritable phenotype. Many genetic factors for
alcohol dependence have been found, but several remain unknown. In search of
additional genetic factors, we examined the association between DSM-IV alcohol
dependence and all common copy number variations (CNV) with good reliability in the
Study of Addiction: Genetics and Environment (SAGE).

All participants in SAGE were interviewed using the Semi-Structured Assessment for the
Genetics of Alcoholism (SSAGA), as a part of three contributing studies. 2,610 nonHispanic European American samples were genotyped on the Illumina Human 1M array.
We performed CNV calling by CNVpartition, PennCNV and QuantiSNP and only CNVs
identified by all three software programs were examined. Association was conducted
with the CNV (as a deletion/duplication) as well as with probes in the CNV region.
Quantitative polymerase chain reaction (qPCR) was used to validate the CNVs in the
laboratory.

CNVs in 6q14.1 (P= 1.04 x10-6) and 5q13.2 (P= 3.37 x10 -4) are significantly associated
with alcohol dependence after adjusting multiple tests. On chromosome 5q13.2 there
were multiple candidate genes previously associated with various neurological disorders.
The region on chromosome 6q14.1 is a gene desert that has been associated with mental
retardation, and language delay. The CNV in 5q13.2 was validated whereas only a
component of the CNV on 6q14.1 was validated by qPCR.
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This is the first study to show an association between DSM-IV alcohol dependence and
common CNVs. CNVs in regions previously associated with neurological disorders may
be associated with alcohol dependence.
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INTRODUCTION
During 2001-2005, excessive alcohol use contributed to about 79,000 deaths and 2.3
million years of potential life lost in the United States [73] . Excessive alcohol
consumption, the third leading cause of preventable death in the United States, can cause
damage to the central and peripheral nervous system, and to nearly every organ system in
the body [74, 75]. It is also strongly correlated with alcohol dependence, a serious
psychiatric disorder that affects about 12% of American adults across their lifetime [76].
Alcohol dependence is a common, complex disease characterized by compulsive and
uncontrolled alcohol consumption despite its negative effects on the drinker's health,
relationships, and social standing.

There is robust evidence for heritable influences on the liability to alcohol dependence
[77]. Siblings of alcohol dependent individuals have a 3-8 fold increased risk of
developing alcoholism [78] with twin studies revealing the heritability of alcohol
dependence to be ≈50% [79-81]. Given its serious public health impact [82] and the
strong evidence for its biological underpinnings, numerous linkage and association
studies have been targeted at gene identification for alcohol dependence [78, 83-86].
Recently, several genome wide association studies (GWAS) queried the genome for
association [83, 87-89]. Results surpassed genome-wide significance in one study of
early-onset male alcoholics [87], but across the multiple efforts, effect sizes were small
and did not replicate. This has generated considerable interest in the examination of other
possible contributors to the “missing heritability” for alcohol dependence. One such
contributor is copy number variations (CNVs).
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CNVs are duplications or deletions of a particular segment of an individual’s genome and
reflect inherent structural instability in the architecture of the genome. They are
prevalent forms of common genetic variation and can have a substantial influence on
gene expression levels [12]. For instance, Mendelian disorders such as Williams-Beuren
Syndrome (due to a deletion at chromosome region 7q11.23) and Charcot-Marie-Tooth
neuropathy Type 1A (caused by duplication at chromosome region 17p11.2 [90, 91] are
attributable to CNVs. Despite the deleterious effects of CNVs and their links to disease,
few studies have examined CNVs in the context of psychiatric illness, particularly
alcohol dependence. This is primarily due to the inherent challenges involved in
identification of what constitutes a CNV. While traditional methods of CNV
identification involve laboratory-based experiments, they can also be identified (or
“called”) using GWAS data where a series of single nucleotide polymorphisms (SNPs) or
“intensity” probes are interrogated for their occurrence in a state other than the expected
disomic (i.e. 2 copy) state. Typically, the intensity of the probe signal that is expected
when two copies of the probe are present is compared with the observed intensity, which
is expected to be enhanced for duplications, or suppressed for deletions. These probes are
routinely included in GWAS chips and thus, as GWAS technology became more
accessible, there was an up-swell in CNV identification efforts. However, this method of
CNV calling from GWAS microarrays can be associated with relatively high error rates.
For instance, in a previous study, we demonstrated the relatively modest concordance in
CNV detection using three widely utilized software packages with varying algorithms. In
that study, we implemented statistical measures that enhance the reliability of the
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detected CNVs using multiple algorithms and further, validated the CNVs identified
using statistical programs by quantitative Polymerase Chain Reaction (qPCR) in the
laboratory [29].

Other challenges of CNV detection include (a) size of the CNV, with smaller CNVs (<10
kb) being harder to detect, (b) number of CNV probes in the region of the CNV, with
fewer probes resulting in greater noise, (c) the general quality of the data (including
artifacts in the SNP data) and genomic waves (intensity variations in normalized GWAS
data), (d) ethnic variations and (e) source of the sample that was genotyped – for instance,
it now well known that deletions and duplications can arise in DNA drawn from cell lines
(i.e. extracting cells from a DNA source and maintaining them in laboratory cultures to
enhance longevity) and, thus CNV detection using cell cultures requires caution. Yet, if
attention is paid to these challenges, CNVs represent a unique route for enquiry into the
genetic architecture of alcohol dependence.

There continues to be a great deal of progress in statistical methods for CNV detection. In
tandem, there is growing excitement about the association between these CNVs and
human behavior and the extent to which these intriguing variations in the human genome
may contribute to that elusive “missing heritability” in complex behavioral phenotypes
and psychiatric illness. While there has been some promise in studies of autism, and
intellectual disabilities [92, 93], as well as schizophrenia and bipolar disorder [94, 95],
research on CNVs in studies of addiction, particularly alcohol dependence, is lacking. In
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this study, we examine the CNVs for DSM-IV alcohol dependence in a large sample of
European-American subjects.
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MATERIALS AND METHODS
Samples
Data were drawn from the Study of Addiction: Genetics and Environment (SAGE) [68].
SAGE is one study of the Gene Environment Association Studies (GENEVA) project
[58]. Cases and controls for the SAGE sample were drawn from 3 contributing projects:
the Collaborative Study on the Genetics of Alcoholism (COGA), the Collaborative Study
on the Genetics of Nicotine Dependence (COGEND) and the Family Study of Cocaine
Dependence (FSCD). While the contributing studies originally ascertained subjects for
alcohol dependence (COGA), nicotine dependence (COGEND: based on an FTND score
of 4 or greater in current smokers, controls being smokers) and for cocaine dependence
(FSCD), the subset of cases selected for genotyping in SAGE were uniformly defined as
those meeting criteria for DSM-IV alcohol dependence (N=1899) while controls
(N=1946) were individuals who reported drinking alcohol but not meeting criteria, during
their lifetime, for alcohol dependence. Of these, 1,186 cases and 1,397 controls are of
self-reported non-Hispanic European-American descent. All participants agreed to share
their DNA and phenotypic information for research purposes and provided written
informed consent following instructions from institutional review boards at all data
collection sites.

Measures
A lifetime diagnosis of DSM-IV alcohol dependence was determined via self-reported
interview information collected using the Semi-Structured Assessment for the Genetics of
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Alcoholism (SSAGA). Controls were individuals who had drunk alcohol atleast once in
their lifetime but did not meet criteria for alcohol dependence.

Genotyping and quality control
The Center for Inherited Disease Research (CIDR) at Johns Hopkins University
genotyped all samples on the Illumina Human 1M array. An extensive data cleaning
effort had been made to ensure data quality. These procedures included, but not limited to,
using HapMap controls, detection of gender mis-annotation and chromosomal anomalies,
cryptic relatedness, population structure, batch effects, Mendelian error detection, and
duplication error detection. A detailed description of data cleaning effort is described
elsewhere [23, 83].

CNV calling
The Illumina 1M array has a total of 1,072,820 probes, predominantly indexed by
polymorphic SNPs. 23,812 of these probes are non-SNP “intensity-only” markers for
CNV detection. All of the 1,072,820 probes were used for the CNV analyses. Three
common programs were used to call CNVs: CNVPartition, PennCNV [28], and
QuantiSNP[61]. Genomic waves were also adjusted when we called CNVs by PennCNV
and QuantiSNP [60]. Both PennCNV and QuantiSNP report a metric score for quality
control purposes. As recommended by QuantiSNP documentation, we removed all CNV
calls that had Log Bayes Factor (LBF) less than 10, as well as poor quality samples based
on quality control measures for CNV analysis, following the approaches described in our
previous work [29]. In total, we genotyped 2,583 non-Hispanic European American

84

samples in SAGE and among them 95 samples failed to pass quality controls for CNV
analysis.

Comparative statistics
The CNV calls from different programs were compared against each other. In our
previous work, we have demonstrated that a CNV that is confirmed by all three CNV
calling programs has a higher reproducibility rate, and thus, a higher reliability [29].
Therefore, we required that in this study, only CNVs detected by all three programs
would be studied.

Association analysis
Logistic regressions were performed on all CNV regions. After identifying potential
regions, individual dummy variables for duplications and deletions were created to
dissect the association signal with DSM-IV alcohol dependence. Several covariates were
included in the model based on the previous GWAS of these data [83], including sex, age,
and two principal components indexing continuous ancestral genetic variation. We also
included a dummy variable to indicate the source of DNA (cell line versus whole blood).
In addition, we ensured that these potentially confounding variables were not directly
associated with the identified CNVs.

CNVs with different starting and ending point
Even when all three programs detect a CNV, they often report different starting and
ending points for the same CNV segment, which leads to computational challenges in
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combining CNV reports. There is a lack of consensus in the research community
regarding this issue and therefore, in addition to studying the CNV as a deletion or
duplication, we adopted an additional straightforward approach for association. First,
SNP probes and intensity-only probes were used to detect CNVs by multiple programs.
Second, a change of copy number at a particular probe was considered detected when all
CNV programs reported CNV segments that cover the probe. Third, association between
alcohol dependence and each probe (assigned the same copy number as the CNV) was
examined. For instance, if a CNV (duplication or deletion) was detected in region X,
using probes (SNP or intensity probes) A, B C, D, E, F and G by three different programs,
then the results from the three programs for each probe were compared against each other
(Figure 4.1). If agreement was reached among three programs, then the CNV for these
probes (Probe D and E) were confirmed and would be used in the following analysis. If
there was disagreement among the three programs, then a missing value was assigned to
these probes (Probe B, C, and F).

Validation
CNVs identified by 3 independent programs were validated in subjects carrying the
variant with quantitative PCR (qPCR). We selected a TaqMan CNV probe in the target
region. The probe was predesigned by Applied Biosystems (Applied Biosytems, Foster
City, CA, USA). Genomic DNA was analyzed with real-time PCR using an ABI-7900
Fast PCR system. Each real-time PCR run included within-plate duplicates. Correction
for sample-to-sample variation was done by simultaneously amplifying a standard CNV
reference assay, RNAse P. Real-time data were analyzed using the comparative Ct
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method [96]. The Ct values of each sample were normalized with the Ct value for the
RNAse P assay. Only the samples with a standard error <0.15 were analyzed. Copy
numbers were calculated using ABI CopyCaller™ Software v1.0.
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RESULTS
Socio-demographic characteristics
Of the 2,583 non-Hispanic European American samples from SAGE, 95 failed to pass
quality control for CNV analysis, leaving 1,140 cases and 1,348 controls. The mean ages
among subjects with alcohol dependence was 38.2 [SD=10.0], and for controls was 39.0
[SD=9.5]. Sixty percent of the cases and 29.2% of the controls were male. As shown in
Table 4.1, cases were more likely to be dependent on nicotine and illicit drugs, including
nicotine, cocaine, and marijuana. They were also more likely to meet criteria for a
lifetime history of conduct disorder and major depression.

Alcohol history
Cases also reported an earlier age of heavy and regular alcohol use, and, by definition,
reported more alcohol symptoms (Table 4.2).

CNV detection
Of the samples that passed quality control, we identified 1,139 CNV regions with length
greater than 50 kb and number of probes not less than 10 [29]. Among them, only 141
CNV regions have frequency higher than 1%. All of these CNV regions had previously
been documented in the database of genetic variants [97]. Thus, after adjusting for
multiple tests, our significance threshold for association analyses is 0.05/141=3.54 x10-4.

Association between CNVs and Alcohol Dependence
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Two CNV regions were significantly associated with alcohol dependence (Table 4.3):
chromosome 6q14.1 (OR=2.86, P= 1.04 x10-6, n=121 subjects with the duplication) and
chromosome 5q13.2 (OR=1.99, P= 3.37 x10 -4, n=59 subjects with the duplication, and
n=58 subjects with deletions). The P values for each probe in these two regions are listed
in Tables 4.4 & 4.5.

Validation using qPCR.
For the CNV at 5q13.2, over 97% of these CNVs were confirmed as true CNVs using
qPCR. However, for 6q14.1, while all deletions were confirmed, none of the duplications
were reproduced via qPCR. This suggests that the result for 6q14.1 should be viewed
with caution.

Relationship among Personality, Alcohol Dependence, and CNVs
We noticed that alcohol dependence is significantly associated with agreeableness
(P=1.04 x10-20), conscientiousness (P=3.93 x10-22), extraversion (P=1.15 x10-12) and
neuroticism (P=6.95 x10-40). . We also found an exceptional P value (P=4.8 x10-5) for
conscientiousness in Chr5: 68,921,426 - 70,412,247, but not for the other four factors.
This observation drives us to hypothesize that Chr5: 68,921,426 - 70,412,247 increase the
risk of alcohol dependence by lowering conscientiousness, or more specifically selfdiscipline (Table 4.6).
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DISCUSSION
These analyses evaluated the association between CNVs and alcohol dependence among
a relatively large sample of alcohol-dependent cases and non-dependent alcohol exposed
controls. We found two regions significantly associated with alcohol dependence: Chr5:
69,916,523- 70,373,564 and chr6:79,034,386-79,090,197. To our knowledge, this is the
first study to connect common CNVs and alcohol dependence.

The identified chromosomal regions have been previously associated with several
neurological and other disorders. Chr5: 69,916,523- 70,373,564 covers several genes,
including SMA4, SERF1, SERF1B, SMN2, SMA3, NAIP, GTF2H2, GTF2H2D and the
downstream OCLN. Among them, SMA3, SMA4 and SMN2 are known to be associated
spinal muscular atrophy [98, 99]. Recent research shows that the genes in this region
have a function in the nervous system [100], including OCLN, another candidate in this
region, which is an integral membrane protein that is required for cytokine-induced
regulation of the tight junction paracellular permeability barrier. Mutations in this gene
are thought to be a cause of pseudo-TORCH syndrome, an autosomal recessive
neurologic disorder that mimics the clinical characteristics (e.g. microcephaly, seizures,
spasticity) attributable to congenital infections due to Toxoplasmosis, Other Agents,
Rubella, Cytomegalovirus or Herpes Simplex [101]. While the CNV in Chr6:79,034,38679,090,197 is located in a gene desert, there is evidence that suggests a link between
chromosome region 6q14.1 and mild mental retardation, language delay, and minor
dysmorphisms [102, 103]. Also, it is hypothesized that non-coding intergenic regions,
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such as this, may contain regulatory elements, such as enhancers and chromosome
scaffold components that are capable of changing gene expression.

The observation that conscientiousness is associated with Chr5: 68,921,426 - 70,412,247
drives us to hypothesize that CNVs at 5q13.2 increase the risk of alcohol dependence by
lowering conscientiousness. But it is possible that this link can be contributed to
confounding effects. We believed it is not likely the case, because agreeableness,
extraversion and neuroticism, all of them are associated with the risk of alcohol
dependence but none of them are linked to this CNV.

We restricted our association tests to non-rare (>1%) CNVs for two reasons. First, the
traditional genome wide association study design has little power to detect rare genetic
variants (<1%), and the case control study design of this project cannot provide enough
power to detect rare CNVs. Second, accuracy of CNV detection diminishes with
decreasing frequency.

In addition we required that all CNVs be reproduced by 3 independent programs, a step
that increases confidence in the results but that raises the potential problem of the same
CNV region being detected with different starting and ending points, which results in
uncertainty on how to combine these different CNV calls. In order to avoid this
controversy, we adopted an intuitive method where we tested each genetic marker instead
of a particular CNV segment. A CNV status is assigned to a particular genetic marker
when all programs report a CNV that covers this probe (Tables 4.4 & 4.5). We validated
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our findings by qPCR – while the region on chromosome 5q13.2 replicated, the
duplication on 6q14.1 did not. This underscores the considerable importance of
experimental validation of CNVs identified using software algorithms.

Our finding of the association between these CNVs and alcohol dependence is
encouraging because it identifies regions previously associated with neurological
disorders, however these findings will require replication. Nonetheless, our study is
amongst the first to examine the role of CNVs in the etiology of alcohol dependence.
This reflects the exciting phase of the post-GWAS genomics era where the quest to
articulate the genetic architecture of serious psychiatric problems like alcohol dependence
moves beyond single SNP association to new frontiers, such as CNVs and rare variants.
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1,348

2,488

No dependence

Total

43.7%

29.8%

60.0%

Gender (male %)

38.7

39.0

38.2

Ave. Age

44.5%

22.5%

Nicotine dependence
70.4%
17.5%

0.0 %
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15.6%

0.0 %

Comorbidity with other addictions*
Cocaine dependence Marijuana dependence
38.3%
34.2%

*All Psychiatric diagnoses were categorized by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.

1,140

Alcohol dependence

Total No.

Table 4.1 - Socio-demographic characteristics

6.7 %

0.0 %

Opiates dependence
14.7%

b.

a.

20.8
19.3

Total

16.7

18.2

15.2

Age when first
got drunk

Regular drinking is defined as drinking once a month for 6 months or more
Largest number of alcoholic drinks consumed in 24 hours

17.8

No dependence

Age of onset of
regular drinking a

Alcohol dependence

Table 4.2 - Alcohol history
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19.1

9.9

30.1

Maximum drinks
per day b

27.5

10.7

54.7

Maximum drinks
per week

2.8

0.7

5.3

Number of alcohol
symptoms endorsed

d.

b.c.

a.

Copy number
Duplication

Chr5: 68,921,426- 70,412,247

chr6:79,034,386-79,090,197

Duplication
Deletion
Non-missing
Duplication
Deletion
Non-missing

43 (4.97%)
22 (2.54%)
865 (100%)
83 (8.99%)
448 (48.54%)
923 (100%)

Cases

CNV frequency
16 (1.59%)
36 (3.57%)
1008 (100%)
38 (3.49%)
542 (49.77%)
1089 (100%)

Controls
SMA4, SERF1, SERF1B,
SMN2, SMA3, NAIP,
GTF2H2, GTF2H2D, OCLNd
Gene desert

1.04 x10-6

1.05

95

Genes

3.37 x10-4

P value c

0.69

Beta b

The starting and the ending point are defined by the probes whose P values have a clear deviation from the rest.
The P value and beta of this region is annotated by the most significant probe in this CNV.
OCLN is located less than 30 kb downstream of this region.

CNV type

Locus a

Table 4.3 - Associations of CNVs and alcohol dependence

Table 4.4 - Associations of each probe and alcohol dependence in Chr5: 68,921,42670,412,247
Chr
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Position
68921426
68930217
68940434
68950807
68956063
68977500
68989477
68999018
69011885
69027097
69031745
69041250
69049740
69061359
69096757
69099351
69111519
69118987
69130746
69145115
69150402
69159243
69172823
69183643
69190743
69199857
69210590
69221673
69233077
69247965
69251715
69262959
69280018
69289210
69304294
69315096
69326897
69331520
69345138
69359352
69369617
69390807
69400684

RS ID or probe ID
cnvGap_CNV_9695.2p30
cnvGap_CNV_9695.2p34
cnvGap_CNV_9695.2p36
cnvGap_CNV_9695.2p40
rs2872744
cnvGap_CNV_9695.2p52
cnvGap_CNV_9695.2p56
cnvGap_CNV_9695.2p60
cnvGap_CNV_9695.2PP1
cnvGap_CNV_9695.2p74
cnvGap_CNV_9695.2p75
cnvGap_CNV_9695.2p77
cnvGap_CNV_9695.2p82
cnvGap_CNV_9695.2p88
cnvGap_CNV_9695.2p10
cnvGap_CNV_9695.2p10
cnvGap_CNV_9695.2p11
cnvGap_CNV_9695.2p11
cnvGap_CNV_9695.2PP2
cnvGap_CNV_9695.2PP2
cnvGap_CNV_9695.2p13
cnvGap_CNV_9695.2p13
cnvGap_CNV_9695.2p14
cnvGap_CNV_9695.2p14
cnvGap_CNV_9695.2p14
cnvGap_CNV_9695.2p14
cnvGap_CNV_9695.2p15
cnvGap_CNV_9695.2p16
cnvGap_CNV_9695.2p16
cnvGap_CNV_9695.2p17
cnvGap_CNV_9695.2p17
cnvGap_CNV_9695.2p18
cnvGap_CNV_9695.3p28
cnvGap_CNV_9695.3PP1
cnvGap_CNV_9695.3p11
cnvGap_CNV_9695.3p18
cnvGap_CNV_9695.3p26
cnvGap_CNV_9695.3p30
cnvGap_CNV_9695.3p39
cnvGap_CNV_9695.3p46
cnvGap_CNV_9695.3p50
cnvGap_CNV_9695.3p54
cnvGap_CNV_9695.3p58
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Beta
1.199816
1.201797
1.022875
0.752159
0.791176
0.731418
0.708313
0.639949
0.768489
0.631037
0.584503
0.610001
0.558177
0.454047
0.432948
0.432948
0.41567
0.415922
0.368784
0.334341
0.353716
0.367197
0.32113
0.321074
0.321015
0.312488
0.321634
0.451626
0.452504
0.464867
0.503588
0.503588
0.509937
0.48309
0.534143
0.520903
0.674162
0.674162
0.722887
0.723277
0.723277
0.756269
0.756269

Std Error
0.384087
0.384229
0.354005
0.317977
0.326499
0.311746
0.313653
0.308121
0.300768
0.291654
0.269701
0.258246
0.250013
0.242656
0.23653
0.23653
0.2376
0.237575
0.233744
0.23186
0.230783
0.229883
0.231953
0.231953
0.231974
0.226807
0.228144
0.238605
0.238721
0.23734
0.235621
0.235621
0.237742
0.239443
0.248472
0.249389
0.253549
0.253549
0.249519
0.249613
0.249613
0.249072
0.249072

P value
0.001785
0.001761
0.003859
0.018008
0.015384
0.018966
0.023929
0.037807
0.010616
0.030491
0.030218
0.018172
0.025576
0.061324
0.067188
0.067188
0.080214
0.079999
0.114628
0.149303
0.125355
0.110194
0.166217
0.166291
0.166407
0.168275
0.158604
0.058388
0.058022
0.050154
0.032575
0.032575
0.031959
0.043637
0.031578
0.036733
0.00784
0.00784
0.003766
0.00376
0.00376
0.002395
0.002395

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

69409672
69428601
69430212
69439738
69455867
69459806
69476562
69510771
69522322
69551174
69566693
69570933
69586554
69590946
69606832
69611483
69629469
69636067
69641101
69651103
69662828
69670671
69685334
69692210
69706422
69713288
69724106
69733571
69741366
69751404
69768625
69773055
69788867
69791981
69809114
69810251
69823637
69831300
69841867
69851260
69865823
69876032
69882833
69893882
69902168
69916523
69922377
69936538

cnvGap_CNV_9695.3p61
cnvGap_CNV_9695.3p65
cnvGap_CNV_9695.3p66
cnvGap_CNV_9695.3p69
cnvGap_CNV_9695.3p74
cnvGap_CNV_9695.3p76
cnvGap_CNV_9695.3p87
cnvGap_CNV_9695.4p77
cnvGap_CNV_9695.4p11
cnvGap_CNV_9695.4p24
cnvGap_CNV_9695.4p27
cnvGap_CNV_9695.4p27
cnvGap_CNV_9695.4p35
cnvGap_CNV_9695.4p39
cnvGap_CNV_9695.4p44
cnvGap_CNV_9695.4p46
cnvGap_CNV_9695.4p53
cnvGap_CNV_9695.4p56
cnvGap_CNV_9695.4p59
cnvGap_CNV_9695.4p63
cnvGap_CNV_9695.4p67
cnvGap_CNV_9695.4PP1
cnvGap_CNV_9695.4p79
cnvGap_CNV_9695.4p83
cnvGap_CNV_9695.4p92
cnvGap_CNV_9695.4p95
cnvGap_CNV_9695.4p10
cnvGap_CNV_9695.4PP2
cnvGap_CNV_9695.4p10
cnvGap_CNV_9695.4p11
cnvGap_CNV_9695.4p11
cnvGap_CNV_9695.4p11
cnvGap_CNV_9695.4p12
cnvGap_CNV_9695.4p12
cnvGap_CNV_9695.4p13
cnvGap_CNV_9695.4p13
cnvGap_CNV_9695.4p13
cnvGap_CNV_9695.4p14
cnvGap_CNV_9695.4p14
cnvGap_CNV_9695.4PP3
cnvGap_CNV_9695.4p15
cnvGap_CNV_9695.4p15
cnvGap_CNV_9695.4PP3
cnvGap_CNV_9695.4PP3
cnvGap_CNV_9695.4p16
cnvGap_CNV_9695.4p16
cnvGap_CNV_9695.4p17
cnvGap_CNV_9695.4PP3
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0.741535
0.7834
0.7834
0.809719
0.667099
0.667099
0.66676
0.714841
0.713733
0.666819
0.683789
0.701269
0.538879
0.538879
0.563723
0.524986
0.485993
0.485993
0.485993
0.486
0.509414
0.460186
0.497897
0.448661
0.4288
0.42941
0.437324
0.371912
0.386067
0.450406
0.528363
0.559303
0.564798
0.58497
0.801829
0.801829
0.837268
0.837268
0.87538
0.875937
0.862827
0.895296
0.895296
0.896231
0.839408
0.929826
0.929826
0.844825

0.249818
0.260774
0.260774
0.26522
0.280284
0.280284
0.280188
0.286388
0.286203
0.270958
0.269716
0.268428
0.235836
0.235836
0.2313
0.227573
0.218098
0.218098
0.218098
0.218117
0.21455
0.212049
0.210767
0.208357
0.202809
0.202791
0.20042
0.191615
0.194716
0.20269
0.213867
0.215967
0.233271
0.238321
0.277339
0.277339
0.275872
0.275872
0.279896
0.27989
0.280838
0.279328
0.279328
0.279376
0.275278
0.270602
0.270602
0.267901

0.002994
0.002663
0.002663
0.002266
0.017309
0.017309
0.017327
0.012558
0.012638
0.013856
0.011238
0.008988
0.022314
0.022314
0.014802
0.021061
0.025859
0.025859
0.025859
0.025869
0.017581
0.029992
0.018161
0.031293
0.034489
0.034217
0.029106
0.052267
0.047399
0.026274
0.013492
0.009604
0.015469
0.014106
0.003838
0.003838
0.002405
0.002405
0.001763
0.001751
0.002124
0.00135
0.00135
0.001337
0.002294
0.00059
0.00059
0.001613

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5*
5
5

69943485
69954494
69973658
69980978
69997937
70002621
70022132
70033323
70054944
70065114
70078585
70093265
70104506
70132660
70145118
70160109
70161507
70179802
70181307
70202676
70212521
70222045
70232726
70245258
70256087
70261872
70274080
70300876
70304036
70309633
70311476
70327006
70335524
70341309
70341452
70342434
70343142
70343220
70351828
70368925
70373564
70391854
70405153

cnvGap_CNV_9695.4p18
cnvGap_CNV_9695.4p18
cnvGap_CNV_9695.4p19
cnvGap_CNV_9695.4p19
cnvGap_CNV_9695.4p20
cnvGap_CNV_9695.4p20
cnvGap_CNV_9695.4p21
cnvGap_CNV_9695.4p22
cnvGap_CNV_9695.4PP5
cnvGap_CNV_9695.4PP5
cnvGap_CNV_9695.4p23
cnvGap_CNV_9695.4p24
cnvGap_CNV_9695.4p24
cnvGap_CNV_9695.4p26
cnvGap_CNV_9695.4p26
cnvGap_CNV_9695.4p27
cnvGap_CNV_9695.4p27
cnvGap_CNV_9695.4p28
cnvGap_CNV_9695.4p28
cnvGap_CNV_9695.4p29
cnvGap_CNV_9695.4p30
cnvGap_CNV_9695.4p30
cnvGap_CNV_9695.4p31
cnvGap_CNV_9695.4p32
cnvGap_CNV_9695.4p32
cnvGap_CNV_9695.4p32
cnvGap_CNV_9695.4p32
cnvGap_CNV_9695.5p24
cnvGap_CNV_9695.5p42
rs575909
cnvGap_CNV_9695.5p73
cnvGap_CNV_9695.5p12
cnvGap_CNV_9695.5p15
rs28751879
rs28538463
rs28447466
rs36065930
rs4976210
cnvGap_CNV_9695.6p46
cnvGap_CNV_9695.6p10
cnvGap_CNV_9695.6p11
cnvGap_CNV_9695.6p16
cnvGap_CNV_9695.6p22

* The probe with the most significant P value in this CNV region.
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0.858466
0.858466
0.756466
0.756384
0.724284
0.731238
0.759332
0.759684
0.764576
0.765482
0.634303
0.601258
0.416646
0.742946
0.550989
0.496704
0.496537
0.515022
0.515022
0.484197
0.495478
0.494999
0.493616
0.512855
0.513487
0.513487
0.603484
0.521426
0.497972
0.472588
0.46997
0.512376
0.553221
0.5665
0.5665
0.566707
0.567762
0.566641
0.620636
0.650221
0.693727
0.55771
0.576782

0.266437
0.266437
0.265982
0.265997
0.262874
0.267667
0.272195
0.272224
0.279212
0.279118
0.286028
0.293154
0.324074
0.34966
0.321841
0.274422
0.274459
0.272403
0.272403
0.260942
0.260042
0.260111
0.260006
0.262521
0.262557
0.262557
0.249562
0.217213
0.213587
0.197371
0.196627
0.169714
0.172349
0.168459
0.168459
0.168305
0.168294
0.171011
0.18749
0.189743
0.193509
0.194912
0.202344

0.001273
0.001273
0.004454
0.004461
0.005865
0.006297
0.005276
0.00526
0.006175
0.006097
0.02658
0.040267
0.198565
0.033606
0.086898
0.070295
0.070428
0.058669
0.058669
0.063515
0.056731
0.057037
0.057633
0.050751
0.050498
0.050498
0.015599
0.016372
0.019729
0.016647
0.016841
0.002536
0.001328
0.000771
0.000771
0.000759
0.000742
0.000921
0.000932
0.000611
0.000337
0.004218
0.004365

Table 4.5 - Associations of each probe and alcohol dependence in Chr6:79,034,38679,090,197
Chr
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6*
6*
6
6
6
6
6
6
6
6
6

Position
79034386
79036117
79039487
79042356
79052979
79056617
79056822
79059458
79063712
79065940
79065999
79067895
79069278
79069674
79070425
79075016
79076024
79076473
79077158
79077999
79078423
79081009
79082584
79083049
79083083
79083326
79086086
79088461
79090197

RS ID or probe ID
rs818258
rs818262
rs818313
rs818310
rs11964123
rs1093580
rs818301
rs6932920
rs6918807
rs6911209
rs6931912
rs9361392
rs818295
rs9448350
rs964927
rs7749022
rs9448356
rs9448357
rs818290
rs7774454
rs818288
rs16889854
rs16889859
rs818285
rs818284
rs9443550
rs9448361
rs818280
rs7773124

Beta
1.208651
1.189742
1.095437
1.07382
1.017069
1.053288
1.053288
1.053288
1.004236
1.003881
1.003881
1.001207
1.005926
1.005926
1.005926
1.01238
1.046794
1.046794
1.046827
1.046827
1.042325
1.00384
0.968943
0.969383
0.965082
0.974056
0.976535
0.964914
0.951371

* The probes with the most significant P value in this CNV region.
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Std Error
0.25355
0.249361
0.232592
0.225953
0.219191
0.217916
0.217916
0.217916
0.212568
0.212539
0.212539
0.212502
0.21264
0.21264
0.21264
0.212543
0.214308
0.214308
0.214304
0.214304
0.214243
0.224986
0.226665
0.226686
0.226739
0.226628
0.226689
0.227086
0.228169

P value
1.87065E-06
1.83165E-06
2.48088E-06
2.01012E-06
3.48217E-06
1.34181E-06
1.34181E-06
1.34181E-06
2.30915E-06
2.32078E-06
2.32078E-06
2.4589E-06
2.23806E-06
2.23806E-06
2.23806E-06
1.90567E-06
1.03678E-06
1.03678E-06
1.03542E-06
1.03542E-06
1.14368E-06
8.12803E-06
1.91323E-05
1.90001E-05
2.07794E-05
1.72314E-05
1.64874E-05
2.1462E-05
3.05157E-05

0.0707

-0.0034
0.0997

0.7075

6.95 x10-40

Openness

100

0.1325

0.2672

-0.0622

1.15 x10

-12

1.59

1.37

-0.88

-3.19

4.8 x10-5

-0.0913

3.93 x10-22

Neuroticism

Extraversion

Conscientiousness

Agreeableness

Chr5: 68,921,426 - 70,412,247
P value
Beta
0.1818
-0.94

Alcohol dependence
P value
Beta
1.04 x10-20
-0.0975

Table 4.6 - The relationship among the FFM dimensions, alcohol dependence and CNVs

0.0010

0.5652

0.1968

0.0226

3.55

-0.45

-1.06

-1.85

Chr6:79,034,386 -79,090,197
P value
Beta
-2.38
0.0020
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A straightforward approach was adopted to treat inconsistent CNV calls from different programs. Three different programs were used
to call CNVs. Figure 4.1 shows that for the same subject, three programs detected a CNV (duplication or deletion) in region X by
using probes (SNP or intensity probes) A, B C, D, E, F and G. The results from the three programs then were compared against each
other. If agreement was reached among three programs, then the CNV calls for these probes (Probe D and E) were confirmed and used
in the following analysis. If there was a disagreement among the three programs, a missing value was assigned (Probe B, C, and F).
Other probes (Probe A and G) did not have copy number changes.

Figure 4.1 - Comparing CNV calls from different programs

Chapter 5: Challenges and directions: an analysis of Genetic Analysis Workshop 17
data by collapsing rare variants within family data
*

This chapter is adapted from: Lin P et al. (2011) Challenges and directions: an analysis
of Genetic Analysis Workshop 17 data by collapsing rare variants within family data.
BMC proceedings. In Press.
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ABSTRACT
Recent studies suggest that the traditional case-control study design does not have
sufficient power to discover rare risk variants. Two different methods—collapsing and
family data—are suggested as alternatives for discovering these rare variants. Compared
with common variants, rare variants have unique characteristics. In this paper, we assess
the distribution of rare variants in family data. We notice that a large number of rare
variants exist only in one or two families and that the association result is largely shaped
by those families. Therefore we explore the possibility of integrating both the collapsing
method and the family data method. This combinational approach offers a potential
power boost for certain causal genes, including VEGFA, VEGFC, SIRT1, SREBF1,
PIK3R3, VLDLR, PLAT, and FLT4, and thus deserves further investigation.
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BACKGROUND
Genome-wide association studies have accelerated the discovery of genetic variants that
cause disease. Thus far, nearly 600 genome-wide association studies have examined
about 150 distinct diseases or traits, and more than 800 SNPs associated with these
diseases or traits have been identified[104]. Recent studies have suggested that rare
variants contribute to common diseases, but the case-control study design does not have
sufficient power to discover rare causal variants.

Two common approaches are used to increase the power to detect rare variants. One
method is to collapse rare variants on the basis of predetermined criteria. By grouping
risk variants together, the frequency of rare risk variants can be increased in the data set.
Extensive research on collapsing has been done for population-based data [105]. Another
approach is to examine family data. The potential advantage of family data is that a
particular rare variant found in an affected individual is more common in that
individual’s family than in subjects randomly sampled in the population.

The Genetic Analysis Workshop 17 (GAW17) is a collaborative effort among researchers
to improve our current understanding of genetic architecture. It provides simulated data
based on real exon sequence data, and thus offers a unique and relatively realistic
opportunity to evaluate statistical genetic methods that are relevant to current analytical
problems. In For this workshop, we designed this a study to (1) test both the collapsing
methodology and the family design in data sets generated with the same biological model,
and (2) assess the power of combining these two approaches: (collapsing rare variants

104

within family data). This study will help guide researchers to design and analyze future
studies for the detection of rare genetic variants.
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METHODS
Family-based association testing
To test genetic associations in family data, investigators need to address the correlation
among family members. Several methods are available [31, 106, 107]. We accounted for
correlated genotypes by using the modified quasi-likelihood score test (MQLS) developed
by Thornton and McPeek [106]. This method is implemented in the computer program
MQLS.

MQLS is an improvement on the previous quasi-likelihood score test, WQLS, developed by
Bourgain et al. [108]. It accounts for the correlations among related individuals by using
a defined kinship matrix and assigns optimal weights depending on the pedigree
information, thus providing an efficient estimator of allele frequency under the null
hypotheses. Interested researchers should refer to Thornton and McPeek’s paper for more
details [106].

Collapsing rare variants within family-based association testing
A causal gene can be shared by more than one or two families, although this gene can
have different rare risk variants in those families. Traditional family-based association
tests fail to combine signals from different rare variants. To address this issue, we
proposed to collapse these rare variants. Many collapsing methods are available. Some
methods simply account for the presence or absence of rare variants, whereas others
assign an adjustable weight to different types of rare variants, based on biological
function or minor allele frequency, and then calculate a final score for each gene [105].
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Currently, there is no conclusive evidence to argue for or against a particular collapsing
method. To generate data that can be analyzed by MQLS, we created a gene indicator that
collapses rare variants within the same gene. Similar to SNPs, the gene indicator is a
dichotomous variable that indicates presence or absence of any rare variant within the
region of interest, so it can be processed by the MQLS program. A gene indicator variable
G for the nth subject is defined as

Gn

⎧ AB
⎨
⎩ AA

if any predefined rare variants exist in a particular gene,
if no predefined rare variants exist in a particular gene.

(1)

Although genotype BB can be defined when both alleles of a particular SNP are the rare
alleles, the likelihood of this situation is small, because we are dealing with rare variants.
We have developed a SAS macro to implement our method with the MQLS program. The
SAS macro is available to interested investigators.

Power analysis
A subset of genes that had sequence data available in the 1000 Genomes Project was
included in this GAW17 project. GAW17 simulated the phenotype based on a predefined
simulation model and generated 200 different phenotype files under the same model.
Thus the 200 replicate phenotype files provide a unique opportunity to estimate power.
We tested associations under different conditions and calculated the power of different
approaches. Power is defined as the proportion of times that a particular test reaches the
significance threshold.
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RESULTS
Distribution of rare variants within family data
The GAW17 data set has 697 subjects (209 case subjects and 488 control subjects) from
8 families. A total of 24,487 SNPs were simulated for 3,205 genes. Fully informative
identical-by-descent (IBD) scores were also provided for each gene.

We defined a SNP as rare if its minor allele frequency (MAF) in the population was less
than 0.01. By this definition, in the GAW17 data there are 18,131 rare SNPs, 56.4% of
which do not exist in the family data. According to the simulation model, 162 SNPs
underlie the disease status. Among them, 145 are rare SNPs. Unfortunately, more than 70%
of these rare SNPs do not exist in the family data. In addition, a large proportion (85%) of
the remaining SNPs exist in only one or two families (Figure 5.1).

Moreover, many existing rare variants are not passed on in the family. Analysis of the
family data shows that 30 of the 42 rare variants that exist in founders are not passed on
to offspring. In fact, only 10 of the 42 rare SNPs (7% of all the causative rare SNPs) have
an allele frequency (frequency in family data) greater than 0.01.

Family-based association test
Because 85% of the 36 rare SNPs found in families exist in only one or two families, it is
expected that only one or two families can contribute to the final association result.
Among the 145 rare SNPs that underlie the disease status, most signals exist in only one
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or two families. The distribution of signals is shown in Figure 5.2, and it matches the
distribution of rare SNPs within families well.

In addition, combining families that have a particular risk allele with families that do not
have the particular risk allele unintentionally diminishes the power. We compared the
association result from all families and the association result from each family. Seventyseven percent of rare causal SNPs have more significant P-values from one family than
from all data analyzed together.

Collapsing rare variants within family-based association test
As we have shown, for a particular rare risk variant, only one or two families contribute
to the signal, but one gene may have multiple risk variants, each of which may be
possessed by different families. Cystic fibrosis transmembrane conductance regulator
(CFTR) is a good example. Since CFTR was identified, more than 1,000 mutations have
been found for cystic fibrosis [109]. And similar to CFTR, a causal gene may have
multiple mutations, and different families may have different risk mutations within the
same gene. Because these different mutations can be designated by a risk gene indicator,
we believe that collapsing those different mutations to a gene indicator may provide an
additional boost on power.

We tested collapsing within family data using the method described in the Methods
section. One particular question we want to address here is whether there is any benefit to
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collapsing within families compared to collapsing in population-based data, which has
been extensively researched.

We set our significance level to a loose level of P < 0.05 for power calculation and
repeated our analysis in the 200 phenotype data sets. We collapsed all rare SNPs (MAF <
0.01) within genes. The SNP for GCKR has a MAF greater than 0.01 and thus was
excluded from analysis. Among 35 available genes, 17 reached the significance threshold.
The power for these genes is shown in Table 5.1. For comparison, we did similar
analyses in the population data with two dummy variables to adjust for ancestry. From
the table, we notice that family-based collapsing is more useful for certain genes.

Among those genes for which the family-based collapsing has power, we set our
significance threshold to the stringent level of 0.05/3,205 = 1.56 × 10−5. The power for
VEGFC and VEGFA is 99% and 94.5%, respectively. Population-based collapsing,
however, has no power to detect these two genes. Among the 200 phenotypes, the
population-based collapsing reported a median P-value of 0.98 for VEGFC and 0.54 for
VEGFA.

Another issue we want to address is whether there is any gain in power for collapsing
within families compared to the family approach without collapsing. We tested each SNP
using MQLS within family data. The result is shown in Table 5.2. The comparison shows
that collapsing may be useful for some variants and may be detrimental for some other
variants. In fact, collapsing a causal variant with a noncausal variant will diminish power.
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We found that SIRT1 and VLDLR have a power drop, but for some other genes, such as
SREBF1, PIK3R3, PLAT, and FLT4, there are considerable power gains. Further analysis
shows that among those genes that have power gains by the family-based collapsing,
many families that possess different risk variants have contributed to the signal.
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DISCUSSION
Recent advances in genome-wide association studies have identified hundreds of
common SNPs that are associated with different diseases, but collectively they can
explain only a small fraction of variation. Many investigators believe that the missing
heritability may be partly explained by the rare variants, which are difficult to discover in
the common case-control study design. One reason that the existing study design does not
have sufficient power is simply because these rare variants are rare. In general, for any
statistical test, a certain number of subjects who possess this particular rare variant are
required in order to obtain enough power. From this perspective, the family design and
the collapsing approach, both of which are potential methods for discovering rare variants,
aim to increase the presence or the frequency of the risk variant or haplotype in the data
set. However, some challenges are associated with these two methods.

It is generally thought that because a rare mutation can be transmitted to offspring, family
data may have more copies of rare mutations than can be found in population-based data.
However, a large number of rare mutations that are possessed by founders are not passed
on in the family data. Among 145 rare SNPs, only 10 have an allele frequency (frequency
in family data) greater than 0.01. This may partly explain the general conclusion reached
in the GAW17 meeting that family data are not particularly helpful for discovering rare
risk variants.

In addition, collapsing should be used with caution. The assumption behind collapsing is
that risk alleles tend to be rare. This assumption may be supported by evolution theory. If
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one new variant is generated by mutation and is beneficial, then this new variant will be
favored by selection and therefore its frequency will increase over time. Similarly,
malicious alleles are selected against, and therefore their frequency will decrease over
time. Moreover, if a nonsynonymous mutation occurs at a conservative gene coding
region, it is likely that the mutation will be malicious, because that is why the sequence is
otherwise conservative. However, some neutral rare variants can exist in the population
as a result of random mutation. Grouping a risk variant with a neutral variant may
decrease the power, as we have shown in Table 5.1.

In GAW17, all risk variants are nonsynonymous SNPs. In Table 5.1, the power is lower
when collapsing all rare variants than when collapsing only nonsynonymous SNPs. It is
tempting to argue that we should collapse only nonsynonymous SNPs. In reality,
however, synonymous SNPs may play a significant role in biological function, for
example, alternative splice site, transcription factor binding site, or even chromatin
structure protein binding site. Meanwhile, nonsynonymous SNPs may have no function at
all. At the protein level, an amino acid change, which is usually the result of
nonsynonymous SNPs, often fails to change the secondary structure and tertiary structure
of a protein and therefore may have no impact on protein function. Although it is
generally difficult to predict whether a synonymous SNP or a nonsynonymous SNP is
biologically functional or not, we believe that the use of prediction algorithms for
function will be helpful. Several function prediction algorithms are available, for example,
SIFT and PolyPhen-2 [110, 111]. Unfortunately, all causal variants in the GAW17
simulation data were chosen based on PolyPhen and SIFT predictions of the likelihood
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that the variant would be deleterious. Thus the application of the function prediction
algorithm to the GAW17 simulation data, which were generated using the same function
prediction algorithm, may not be illuminating.

One purpose of this study is to cast new light on future study designs. We noticed that in
family data, the association signals exist in only one or two families. We also noticed that
combining these families with families that do not possess these risk variants
unintentionally diminishes power. Therefore we argue that, given a limited sample size, a
large pedigree may be more useful for discovering rare risk variants. Although many rare
variants cannot be discovered, a large pedigree is still useful because at least some causal
rare variants are more likely to be found.

In conjunction with association testing, linkage can identify regions of interest. Therefore
regional sequencing can be done instead of whole genome sequencing. In addition, the
selection of the most informative families or family members may further reduce the total
genotyping cost. In addition, the use of extremes of a phenotypic distribution may
provide tremendous information and reduce the required sample size [112].

In this study, we tested collapsing within family data, which combines the two widely
proposed methods: the family design and the collapsing approach. The new
combinational method provides considerable power gain for some genes. Although we
noticed that the power gain is obtained at the cost of power for some other genes, this is
still useful, especially if the alternative is that nothing can be found. As we have shown in
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this paper, this method can be useful for discovering novel variants associated with
disease, and thus it merits further study.
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CONCLUSIONS
Family data are believed to be one way to increase the presence of rare variants in the
data set. But a large number of rare risk variants cannot be sampled in the family data.
Even for existing rare risk variants, a large proportion of them are not passed on in the
family. Many existing rare risk variants are seen in only one or two families, and the
result from association is largely shaped by those families. To aggregate signals from
different rare variants in different families, we integrated the collapsing method within
the family data method. To our knowledge, this is the first attempt in the literature to do
collapsing within family data. This combinational approach offers a promising power
boost for certain causal genes and thus deserves further investigation.
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Number of
nonsynonymo
us SNPs
2
1
14
16
2
15
11
5
9
1
3
6
17
25
6
5
5

Gene
VEGFA
VEGFC
SIRT1
SREBF1
PIK3R3
VLDLR
PLAT
FLT4
KDR
PIK3C3
PTK2B
SOS2
FLT1
BCHE
PDGFD
HIF1A
PTK2
PIK3C2
1
22
38
B
1
SHC1
3
3
6
VNN1
4
2
a
All rare SNPs were collapsed.
b
Only nonsynonymous rare SNPs were collapsed.

Chromosom
e
6
4
10
17
1
9
8
5
4
18
8
14
13
3
11
14
8

Number of
synonymous
SNPs
2
0
9
5
3
8
14
3
5
5
6
1
8
3
0
2
4
23
1
1

60
6
6
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Number of
risk SNPs
1
1
9
10
1
8
8
2
8
1
3
2
8
13
4
3
2

Total
number of
SNPs
4
1
23
21
5
23
25
8
14
6
9
7
25
26
6
7
9
0
1

2

Power (All)
(%)a
100
100
19
19
11
10
8
6
0
0
0
0
2
0
6
0
0
0
2

0

Power
(nonsynonymous
) (%)b
100
100
47
36
1
4
34
13
0
0
0
0
1
1
6
0
0

Family

13
7

14

5
13

16

Population
Power
(nonsynonymous
Power
) (%)b
(All) (%)a
13
10
0
0
7
8
17
18
2
2
10
9
6
7
15
15
45
35
38
0
31
4
22
25
21
17
19
19
19
19
17
17
14
6

Power is calculated based on the threshold P < 0.05. Because of limited space, only those genes whose power is greater than 10% are
shown.

Table 5.1 - Comparison of collapsing within family data and collapsing within population-based data

Number of
nonsynonymous
SNPs
2
1
14
15
16
2
11
5

Chromosome
Gene
6
VEGFA
4
VEGFC
10
SIRT1
9
VLDLR
17
SREBF1
1
PIK3R3
8
PLAT
5
FLT4
a
All rare SNPs were collapsed.
b
Only nonsynonymous rare SNPs were collapsed.

Number of
synonymous
SNPs
2
0
9
8
5
3
14
3
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Total number
of SNPs
4
1
23
23
21
5
25
8

Number of
risk SNPs
1
1
9
8
10
1
8
2
Power (All)
(%)a
100.0
100.0
19.0
10.0
18.5
11.0
8.0
6.0

Power
(nonsynonymous)
(%)b
100.0
100.0
47
3.50
36
1
34
12.50

Collapsing
Noncollapsing,
power (%)
100.0
100.0
99
58.50
22.50
0
0
0

Power is calculated based on the threshold P < 0.05. Because of limited space, only those genes whose power is greater than 10% are
shown.

Table 5.2 - Comparison of family data with collapsing and family data without collapsing

Figure 5.1 - Distribution of rare causal SNPs within families

In the GAW17 data set, 145 of 162 casual SNPs are rare variants. Of these 145 rare
variants, 103 do not exist in the family data. Eighty-five percent of the existing rare
variants exist in only one or two families. The number above each bar indicates the exact
number of rare SNPs in this category. It partly explains why many rare variants cannot be
discovered using family data.
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Figure 5.2 - Distribution of association signals within families

Each category indicates the number of families that report an association signal for each
SNP. The number above each bar indicates the total number of rare causal SNPs in this
category. The distribution of association signals matches well to the distribution of rare
SNPs within families. It shows that when all families are analyzed together, the final
result is largely shaped by only a few families.

120

Chapter 6: Conclusions and Future Directions
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CONCLUSIONS
The human genome has around 3 billion base pairs of DNA and stores most, if not all, the
information needed to build up a human being from scratch. Our very existence − both
physical existence and mental existence − is determined by the combinational effects of
gene and environment. Human diseases, ranging from Alzheimer’s disease to Zadik
Barak Levin syndrome, are no exceptions. Since the discovery of Mendel’s laws, one of
the most challenging problems in genetic research is to find and characterize different
genetic variants that contribute to various human diseases. In the past decade, the
research community has made impressive progress. New technologies were introduced,
numerous methods were proposed and a large number of disease-associated genes were
found [6]. The work presented here has largely reflected the recent development of this
field, and as a result this work presented several new methods to address current research
challenges.

One of the most important developments in the past 5 years is genotyping imputation [8].
Genotyping imputation allows researchers to evaluate the evidence for association at the
genetic markers that are not directly-genotyped. It can improve power of individual scans
and is particularly useful for combining results from different studies. However, there are
two situations for which imputation has been problematic: (1) polymorphisms with low
minor allele frequency (MAF), and (2) datasets where subjects are genotyped on different
platforms. The imputation quality score that we introduced in Chapter 2 is sufficient to
address these two issues. After filtering out poorly-imputed SNPs, we were able to
remove thousands of false positives and obtain an acceptable Q-Q plot. We concluded
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that IQS is particularly useful for SNPs with low minor allele frequency and when
datasets are genotyped on different platforms.

By using the same approach described in chapter 2, we discovered that CNVs with low
minor allele frequency also have similar problems in the dataset of the CNV Discovery
Project [113]. Our intent was to evaluate the relative performance of CNV calling in a
genome wide scale despite the lack of experimental validation at individual CNV loci.
The underlying rational is that whether a CNV that is called the first time can be
confirmed the second time is restricted by both sensitivity and specificity. This kind of
information in turn can give us some clues on sensitivity and specificity. By using the
proposed method, we found that the positive predictive rate increases with the number of
probes in the CNV and the size of the CNV. We also noticed that CNVs reported by
multiple programs have a higher reproducibility rate and positive predicted rate. Our
method was intended to find an efficient way to evaluate CNV calling in a genome wide
scale. The fact that CNVs that are reported by multiple programs have a higher reliability
is not part of our method, but rather our observation. The exact reasons for our
observation may need further investigation, but it may be due to the fact that real CNVs
have a more distinguished pattern that is easier to be spotted by different programs.

We applied our CNV methods to the Study of Addiction: Genetics and Environment [68].
Our analysis revealed that CNVs in 6q14.1 (P= 1.04 x10-6) and 5q13.2 (P= 3.37 x10 -4)
are significantly associated with alcohol dependence after adjusting multiple tests. The
following qPCR experiments on these two CNV loci showed over a 97% agreement rate
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for our CNV calls. The experimental validation not only confirmed the association signal
for alcohol dependence, but also demonstrated the power and legitimacy of our methods.

Interestingly, we also noticed the connection between alcohol dependence and
personality. Among the five factors of the FFM dimensions, agreeableness (P=1.04 x1020

), conscientiousness (P=3.93 x10-22), extraversion (P=1.15 x10-12) and neuroticism

(P=6.95 x10-40) are all significantly associated with alcohol dependence. We also found
an exceptional P value (P=4.8 x10-5) for conscientiousness in Chr5: 68,921,426 70,412,247, but not for the other four factors. This observation drives us to hypothesize
that Chr5: 68,921,426 - 70,412,247 increases the risk of alcohol dependence by lowering
conscientiousness, or more specifically self-discipline. Because conscientiousness and
alcohol dependence are associated, it is possible that this link can be contributed to
confounding effects. We believed that this is not likely the case, because agreeableness,
extraversion and neuroticism are all associated with the risk of alcohol dependence but
none of them are linked to Chr5: 68,921,426 - 70,412,247.

As the whole research community shifted its focus from common variants to rare variants
[30], we also explored the possibility of applying our methods described in Chapter 2 & 3
to rare variants. Particularly, we noticed that some of the issues that we intended to
address in Chapter 2 & 3 arise from rare variants. We had evidence that our methods are
applicable to rare variants as well. However, we also noticed that our methods cannot
address one major problem of detecting rare variants – the lack of power. By taking
advantage of the simulation data from the Genetic Analysis Workshop, we integrated
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both the collapsing method and the family data method in an attempt to increase power.
We concluded that our combinational approach offers a substantial power boost for
certain causal genes that cannot be discovered otherwise.

There are several highlights of the work presented here. The motivation for Chapter 2 and
Chapter 3 was to address data quality of imputation and CNV calling. The data quality
issues are more noticeable when the allele frequency of SNPs and CNVs becomes rarer.
Chapter 5 confirmed the commonly-held belief that traditional study design does not have
sufficient power to discover rare variants, and hence proposed a new method to increase
power. As a result, the work presented here aimed to provide solutions to the issues
regarding the currently-ongoing transition from common variant research to rare variant
research.

Many new methods are justifiable in mathematical theory, but may not be applicable in
real data. The work presented here was also fortunate because it reaches beyond theory.
The method and the Imputation Quality Score proposed in Chapter 2 were used in real
SAGE data to assess imputation quality of some interesting SNPs, especially those at
some target loci. The methods proposed in Chapter 3 were used to improve CNV calling
in the alcohol dependence study and the BMI study. The results of connecting CNV calls
and alcohol dependence by the method described in Chapter 3 were reported in detail in
Chapter 4. Though at the current stage, we do not have enough sequencing data to test the
method described in Chapter 5. But it is expected that the method we propose here will
be applied to real sequencing data when it soon becomes available. In fact, several groups
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in the Genetic Analysis Workshop showed great interest in this combinational approach
or some similar methods.

Another highlight of this work is that we had in silico and experimental validation for the
methods described here. In Chapter 2, we used IQS to filter out poorly-imputed SNPs,
and successfully removed many false positives. In Chapter 4, we did qPCR to validate
CNVs that were called by the methods described in Chapter 3. We were able to confirm
over 97% of CNV calls. The in silico and experimental validation showed the methods
presented here are valid and can be very useful for future research.
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FUTURE DIRECTIONS
The work presented here has provided several solutions to the current research challenges,
but it also has prompted a need to investigate further.

As more and more genome wide association studies are completed, imputation will
become more popular, and meta-analysis based on imputation may become a routine
procedure. As a result, over-estimation of the quality of imputation due to chance
agreement will be more common. Based on our method, a database can be constructed to
document poorly-imputed SNPs and used to remove false positive associations. We
envision this as a dynamic database to be updated when new datasets include subjects
genotyped on multiple platforms. The future database will include, but will not be limited
to, IQS scores for the following imputations: (1) from Affymetrix 6.0 to Illumina 1M, (2)
from Illumina 1M to Affymetrix 6.0, (3) from Illumina 300K to Affymetrix 6.0 plus
Illumina 1M, (4) from Illumina 550K to Affymetrix 6.0 plus Illumina 1M, and (5) from
Affymetrix 5.0 to Affymetrix 6.0 plus Illumina 1M. We expected that this database can
greatly help decrease the amount of false positive findings, making follow up of positive
associations practical. In order to successfully build up and maintain a database proposed
here, we anticipate a server with great computation capability and a team with good
programming skills.

The methods that we introduced in Chapter 3 are a short-cut to evaluate CNV calling
accuracy in a large scale. We concluded that the positive predictive rate increases with
number of probes and the size of CNVs and that CNVs reported by multiple programs
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have a higher reliability. We believed that our general conclusion can hold true
concerning other studies, but we also noticed some variations among different platforms.
We expect that it will be more useful if we can provide a user-friendly program to
different researchers so that they can evaluate the performance of CNV calling in the
platform they have chosen.

Our finding of genome-wide association between alcohol dependence and the CNVs at
6q14.1 and 5q13.2 is encouraging. These two regions were previously shown to be
associated with neurological disorders. But like most genome wide association studies,
replication in an independent dataset is necessary. Unfortunately, no datasets with both
appropriate genotyping and alcohol dependence measures are currently available. We are
looking forward to new studies that can be used to validate our findings.

SAGE also includes a large number of addiction-related covariates. These covariates may
be interesting to many researchers, for example, height, weight, BMI, the number of
cigarettes and drinks per day, pre-term birth and age at menarche etc. It can be extremely
rewarding to study the connection between these covariates and genetic variants.
Particularly, we can further investigate the relationship between CNVs and these different
traits by using the methods described in Chapter 3 & 4. SAGE also has genotypes for
African Americans. We expect that it will be equally rewarding to compare and contrast
our findings between European Americans and African Americans [114].
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We discussed our combinational approach to increase power for rare variants in Chapter
5. But we also noticed that the power gain is obtained at the cost of power for some other
genes. Further study is required. Particularly, we expected an improved method that
gives different weight to SNPs in the collapsing process based on SNP function. Several
function prediction algorithms are available, for example, SIFT and PolyPhen-2 [110,
111]. We believed that the use of prediction algorithms for function will be helpful. In
conjunction with association testing, linkage can identify regions of interest. Sequencing
may only need to target regions that are discovered by linkage. In addition, the selection
of the most informative families may further reduce the total genotyping cost. The use of
extremes of a phenotypic distribution may further provide additional information [112].
Moreover, with the help of imputation, we may only need to do sequencing on a limited
number of family members to obtain the whole genome sequencing data for all members
of a family. All of these directions are promising and have the potential to make an
impact in this field, but it takes time and effort to complete.

The work presented here is in parallel with the current development of genetic research
and provides a blueprint for the future. At the present stage, we still know little about
human disease and human gene. Even though hundreds of genome-wide association
studies turned up thousands of genetic variants, they did very little to predict disease risk
[115]. More research still needs to be done in order to better appreciate the relationship
between gene and disease. But since the human genome only has 3 billion base pairs of
DNA, compared to other disciplines without known boundaries, we should feel fortunate,
because in the end we are searching in a finite universe.
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